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ABSTRACT
METHODS TO INCREASE TEMOZOLOMIDE SENSITIVITY IN GLIOBLASTOMA
MULTIFORME: MANIPULATING PARP-1 AND MGMT
By
Vanessa Loraine Thibado

Glioblastoma multiforme (GBM) is the most malignant and frequent primary
brain tumor in adults. These tumors expand quickly and tend to recur despite surgery,
radiation, and chemotherapy treatments. Alkylating agents, such as Temozolomide
(TMZ), are currently the chemotherapy drugs of choice. Resistance to alkylating agents
via direct DNA repair by O6-methylguanine methyltransferase (MGMT) has arisen as a
significant barrier to effective treatment. Poly(ADP-ribose) polymerase-1 (PARP-1) is
activated by binding to DNA breaks, and has functions related to the DNA repair done by
MGMT. Therefore, inhibition of PARP-1 has been associated with increased sensitivity
to DNA-alkylating agents. The goal of this research was to characterize several PARP
and MGMT manipulating treatments in four glioblastoma cell lines. Clinically relevant
silencing methods were investigated and dose response assays were used for determining
the efficacy of treatments. Research studies such as this are important in the identification
of therapies that can overcome drug resistance, lessen cytotoxic side effects, and
ultimately improve the prognosis of glioblastoma patients.
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INTRODUCTION

Malignant tumors derived from glial cells, which form the supportive tissue of
the brain, are the most common type of central nervous system tumor (Schor, 2009).
Among these, glioblastoma multiforme (GBM) is the most aggressive and frequent
primary brain tumor in adults. According to 2008 statistics from the American Cancer
Society, glial neoplasms represent 0.5-1% of the overall cancer incidence in Western
countries. The standard of care for newly diagnosed GBM includes surgery, followed by
concomitant external beam radiation therapy with temozolomide (TMZ) (Yip et al.,
2009). Unfortunately, the median survival for these GBM patients remains
approximately one year despite the recent addition of TMZ to the standard of care
(Johannessen et al., 2008). These tumors present a number of defenses that make them
therapeutically challenging, most notably blood-brain barrier penetration and multiple
mechanisms for pharmacoresistance. Additionally, the rapid recurrence of GBM remains
a major obstacle to successful treatment.
The normal effects of DNA repair are an important issue when considering
treatment of pharmacoresistant glioblastoma. A well known class of chemotherapy drugs,
such as TMZ, act by adding a methyl group to the DNA which causes base pair mismatch and activates futile repair mechanisms, ultimately resulting in cell death.
Resistance to this class of chemotherapeutic drugs occurs when tumor cells possess an
enzyme called O6-methylguanine methyltransferase (MGMT), capable of reversing
chemotherapy-induced events that would otherwise lead to cell death in treated cells
(Hegi et al., 2008). MGMT expression varies between individuals and clinical outcome

has been shown to correlate with expression levels in patients, with worse prognoses for
patients with higher MGMT levels (Hegi et al., 2005). Thus far, there has been limited
success with combination therapies that target the MGMT enzyme, due in part to serious
toxic side effects (Liu and Gerson, 2006). However, targeting alternative pathways offers
new directions to try to overcome pharmacoresistance.
When approaching adjuvant or concomitant chemotherapy options it is
evolutionarily useful to target multiple pathways. In this way, it should take the cancer
cells longer to evolve chemoresistant mechanisms. This reasoning has been applied to
findings using BCNU, a chemotherapy agent that depletes MGMT, but has serious issues
with acquired resistance (Schor, 2009). In resistant tumors, activation of the Fanconi
anemia pathway for DNA damage repair was observed (Chen et al., 2007). PARP-1 has
been implicated in this pathway, in addition to several other DNA damage repair
pathways important in mediating chemoresistance in glioblastoma (Curtin, 2007).
Moreover, the identification of MGMT promoter methylation as a predictive prognostic
indicator of benefit from TMZ therapy could also have prognostic value for therapeutics
targeting pathways that increase the antitumor efficacy of TMZ (Hegi et al., 2008).
The research presented in this thesis investigates clinically relevant silencing
methods and the effects of temozolomide, PARP-inhibition, and MGMT and PARP-1
siRNA treatment on four GBM cell lines. Inhibition of PARP-1 has been associated with
increased sensitivity to chemotherapy agents like TMZ, the effect of PARP-1 inhibition
and PARP-1 siRNA treatment was explored. Thus, combination studies of MGMT and
PARP-1 manipulation were done to compare the most effective method for increasing the
sensitivity to TMZ in the GBM cell lines.

CHAPTER ONE: POLY (ADP-RIBOSE) POLYMERASE-1

Poly (ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme that performs key
roles in a wide variety of cellular processes. PARP-1 synthesizes poly(ADP-ribose)
(PAR) from its substrate, nicotinamide adenine dinucleotide (NAD+), which it uses for
covalent post-transcriptional modification of nuclear proteins (D'Amours et al., 1999).
PARP-1 proteins are found exclusively in the nucleus, as shown by conventional
fluorescence microscopy; however, rather than homogenous distribution within the
nucleus, PARP-1 associates with specific structures (Concha et al., 1989). The
poly(ADP-ribosyl)ation (PARylation) reaction has been implicated in diverse signaling
and regulation pathways: chromatin modulation, transcriptional regulation, mitotic
apparatus formation, cell death pathways and DNA damage detection and repair (Kraus,
2008). These cellular and molecular roles are necessary for multiple physiologic
processes including overall genome maintenance, neuronal function, aging, inflammatory
responses and carcinogenesis, among others (Kim et al., 2005). Some of the roles that
PARP-1 plays have recently been targeted for drug development to be utilized in stroke
and cancer therapies(Ratnam and Low, 2007).

STRUCTURE AND FUNCTION
The ADPRT gene is located on the long arm of chromosome one and encodes the
113 kDa PARP-1 protein. There are three major domains that contribute to the
multifunctional enzymatic abilities of PARP-1. The N-terminal DNA binding domain
(DBD) contains two zinc fingers, a nuclear localization signal, and a third zinc binding

domain. The zinc fingers recognize and mediate binding to altered DNA structures such
as single and double strand breaks, cruciforms, crossovers and nucleosomes, rather than
specific DNA sequences (Kim et al., 2005). Overall the DBD contains a high proportion
of basic residues which probably help PARP-1 interact with DNA via charge attraction.
A central automodification domain (CAD) contains a BRCT domain with a leucine
zipper. Primary structure analysis reveals 15 conserved glutamate residues, which serve
as the target in PARP-1 automodification via PARylation (Kawaichi et al., 1981). The
BRCT motif is important in protein-protein interactions, allowing interacting proteins to
establish strong and specific associations (D'Amours et al., 1999). The catalytic domain is
located at the C-terminal and contains the NAD+ binding domain and the “PARP
signature”. The basal activity of PARP-1 is low until DNA binding through the DBD
domain and protein-protein interactions mediated via the CAD allosterically activate the
catalytic domain of PARP-1, which is responsible for PARylation (Kraus, 2008). These
structural features contribute to the myriad functions PARP-1 is capable of within the
nucleus.

BIOCHEMISTRY AND REGULATION OF PAR
Called the “third type of nucleic acid” by some PARP-enthusiasts, PAR was
discovered in 1963 (Chambon et al., 1963). PAR is a polymer of repeating ADP-ribose
units with a heterogeneous nature that suggests different forms of PAR could have
distinct functions within the cell (D'Amours et al., 1999). Each PAR residue has chemical
properties that allow specific interactions: adenine can base stack and hydrogen bond,
and the two phosphate groups carry negative charges (Kim et al., 2005). In addition, the

site specific covalent addition of a large, negatively charged PAR polymer on proteins
could have profound effects on the activity of acceptor proteins (D'Amours et al., 1999).
This is especially true for proteins that interact with DNA, which accounts for many of
PARP-1‟s functions within the cell. Anabolic PARylation reactions are under the control
of PARP-1; however, the catabolism of PAR requires additional enzymes, poly(ADPribose) glycohydrolase (PARG) and an ADP-ribosyl protein lyase, which work together
to hydrolyze the glycosidic linkages between ADP-ribose units to generate free ADPribose (Kim et al., 2005). Thus, PAR polymers have a transient nature in cells, controlled
mainly by the opposing actions of PARP-1 and PARG and the regulatory mechanisms
governing these two enzymes.
PARP-1 has a low basal enzymatic activity, but can be potently activated by
interacting with DNA and protein binding partners. PARG is also regulated in more than
one way. A single gene encodes multiple PARG proteins, produced by alternative mRNA
splicing (Davidovic et al., 2001). One isoform contains a nuclear localization signal, and
thus resides in the nucleus. However, the other isoform remains in the cytoplasm because
it lacks a nuclear localization signal (Meyer-Ficca et al., 2004). There has been little
research to understand why a significant portion of PARG enzyme is located in the
cytoplasm when the PARylation reactions that it regulates occur in the nucleus. This
suggests that nucleo-cytoplasmic shuttling may participate in PARG regulation.
Functional studies of PARG have been limited and most studies have utilized gene
disruption (Schreiber et al., 2006). There is still much work to be done to elucidate the
reasons for two distinct populations of PARG and the potential function of the different
isoforms. The covalent modification of acceptor proteins by PARP-1 and subsequent

alterations by PARG, provide numerous ways to control acceptor protein activity and
potentially implicate the PARylation reaction mediated by PARP-1 in a number of
functional roles within the cell. Additionally, PARG has a higher affinity for some types
of PAR chains (for example, long linear polymers), which results in two distinct
populations of polymers in the cell (D'Amours et al., 1999). This suggests that the
heterogeneous PAR forms could have multiple roles in signaling.

MECHANISM FOR DNA DAMAGE DETECTION
A model of PARP-1 shuttling involves PARP-1 binding damaged DNA via the
DBD, prompting automodification, which results in a negative charge buildup on PARP1 (D'Amours et al., 1999). The charge repulsion results in a gradual loss of affinity for the
DNA and PARP-1 dissociates, with PAR chains subsequently hydrolyzed by PARG.
PARP-1 is then able to resume an additional enzymatic cycle when additional DNA
damage is sensed. Although not specifically mentioned in the model, PARP-1 binding
relaxes chromatin at the site of DNA damage, which would allow room for repair
complexes to aggregate (D'Amours et al., 1999). This model does not examine at which
point PARP-1 is involved in recruiting additional repair proteins to sites of DNA damage,
which probably occurs while PARP-1 is still associated with the DNA. Additionally, the
DNA-dependent PARylation of acceptor proteins by PARP-1 also occurs, however,
whether PAR is added to repair proteins or recognized by repair proteins will require
further characterization and may be situation specific.
Upon binding DNA and becoming catalytically active, in addition to
automodification, PARP-1 is also able to attach to PAR units, to PARylate, other

proteins. A specific PAR-binding sequence motif of 20 amino acids has been identified in
several proteins involved in DNA damage checkpoints and repair including the tumor
suppressor protein p53, mismatch repair protein MSH6, the repair protein DNA ligase III,
a scaffolding protein XRCC1, the kinase DNA-PK, a DNA double-stranded break
response protein Ku70, synthesizing proteins DNA polymerase-ε and -β, and others
(Burkle, 2001). Notably, several of these proteins are involved in the base excision repair
(BER) pathway and thus implicate PARP-1 in BER functions within cells. Multiple lines
of evidence corroborate this claim; notably, PARylation reactions are initiated by the
types of DNA damage that incites BER activity and PARP-1 inhibition results in BER
inhibition in vivo and in vitro (D'Amours et al., 1999). XRCC1, a scaffold protein
necessary for stimulating BER enzymes, interacts preferentially with automodified
PARP-1 in vitro, supporting observations in vivo that XRCC1 exhibits PAR-dependent
recruitment to damaged DNA to incite additional BER activities (Schreiber et al., 2006).
Additionally, PARP-1 knockout mice treated with DNA damaging agents exhibit
increased sister chromatid exchanges and chromatid breaks – indicating in addition to a
role in DNA repair, whole genome stability is affected upon losing PARP-1 function
(Burkle, 2001).

SITUATION SPECIFIC PARYLATION: DNA DAMAGE
DNA-damage dependent PAR synthesis has subtle, yet important, differences
from the schemes typically presented, which more appropriately describe PAR synthesis
on acceptor proteins. Most importantly, synthesis of PAR after DNA damage has specific
functions, rather than non-DNA damage dependent synthesis wherein PARylation acts on

a less situation-specific basis to modify the activity of nuclear proteins. It has been shown
that a transient topoisomerase IIβ-induced double stranded breaks (DSBs) resulted in the
activation of PARP-1, in addition to previous observations by multiple research groups
that single stranded breaks (SSBs) are able to potently activate PARP-1 (D'Amours et al.,
1999; Ju et al., 2006). In either case, the PAR production resulting from DNA damage
has distinct functions: PARylation of histones H1 and H2B, PAR mediated signaling of
DNA damage and recruitment of base excision repair machinery (Schreiber et al., 2006).
Although the PARylation of histone proteins is functionally the same as previously
described PAR roles, providing a signal and recruiting additional proteins are alternate
functions for PAR formation. Research suggests that the level of PARP-1 activation (and
thus the level of PAR production) due to SSBs or DSBs may serve as a signal for the
specific type of damage done, with DSBs accumulating more PAR at the site of DNA
damage (D'Amours et al., 1999). The signal and recruitment functions provide additional
means for PARP-1 mediated roles within the cell.
The first indications for the role of PARP-1 in DNA damage repair came from
experiments that observed a marked decrease in NAD+ levels in cells exposed to DNAdamaging agents with a concomitant increase in PAR polymers (D'Amours et al., 1999).
In three independent studies using knockout mice, it was observed that when disrupting
different exons of PARP-1, BER occurred at a slower rate and overall genome instability
increased, as defined by amplified sister chromatid exchange (Shall and de Murcia,
2000). Furthermore, upon binding breaks in DNA, the catalytic activity of PARP-1
increases as much as 500-fold over basal levels, implying that DNA damage is an
important trigger of PARP-1 activity (Kim et al., 2005). Therefore, resultant PAR

production could act as a marker for DNA damage in multiple capacities, as previously
suggested.

CURRENT PARP RESEARCH
The most recently published articles indicate PARP inhibition is relevant to the
therapy of multiple types of cancer. Several clinical studies are underway investigating
the therapeutic potential of PARP inhibitors as monotherapy and in combination with
temozolomide, platinum drugs, topoisomerase poisons, and ionizing radiation
(Mangerich and Burkle, 2011). As discussed later, the mechanism for PARP inhibition,
specifically in models using combination therapy with Temozolomide, has been clearly
elucidated and offers several advantageous features. Additionally, with the advent of
clinically relevant silencing methods, it may be possible to target specific proteins in
cancer cells to render them sensitive to chemotherapy drugs.
The research presented in this thesis investigates clinically relevant silencing
methods and the effects of temozolomide, PARP-inhibition, and MGMT and PARP-1
siRNA treatment on four GBM cell lines. There are currently many methods available for
silencing specific proteins in vitro, but in order for this research to be translatable to
human studies it was important to find a clinically relevant method for in vivo silencing.
Next, while TMZ has been established as the standard of care for GBM, in order to do
additional studies it was necessary to establish a consistent method for creating TMZ
dose response curves in the cells of interest. Since inhibition of PARP-1 has been
associated with increased sensitivity to chemotherapy agents like TMZ, the effect of
PARP-1 inhibition and PARP-1 siRNA treatment was explored. Finally, because the

literature shows a strong correlation between MGMT activity and increased resistance to
TMZ, combination studies were done to compare the most effective method for
increasing the sensitivity to TMZ in the GBM cell lines.

CHAPTER TWO: RNA INTERFERENCE

RNA interference (RNAi) is a major gene regulation mechanism in eukaryotic
cells and can be experimentally exploited to silence gene expression through the use of
exogenous short interfering RNA (siRNA). The clinical application of RNAi is limited,
however, due to inadequate methods of siRNA delivery and its relative instability
(Behlke, 2006). Chemical modifications making siRNA more resistant to nuclease and
nonspecific degradation are variably effective (Elmen et al., 2005). Perhaps more
pertinent to successful site specific treatment using siRNA are studies examining delivery
methods, particularly those suitable for human use. While the route of administration will
be definitive in total dose necessary, tissue distribution, and potential side effects, the
delivery „vehicle‟ by which the siRNA enters the cell will be the most important variable
in treatment efficacy.
Due to the high negative charge density of nucleic acids, cationic polymers, which
can bind siRNA and neutralize charge to facilitate transport across the cell membrane,
have gained notoriety as delivery reagents (Behlke, 2006). These reagents do not disrupt
the cell membrane, and are better suited for clinical use for obvious reasons.
Polyethylenimine (PEI) is one such cationic polymer currently being used as a siRNA
delivery vehicle in clinical models. Thus, by examining PEI reagents for silencing
efficacy in an in vitro GBM model, it may represent a more clinically relevant model for
translational research.

RNAi MECHANISM
While there had been evidence for post-transcriptional gene silencing, it was the
work done by Andrew Fire and Craig C. Mello in C. elegans that finally described RNA
interference (Fire et al., 1998). Eight years after publishing their work, they won the 2006
Nobel Prize in Physiology or Medicine. In addition to uncovering a new cellular feature
for controlling genetic information, this discovery transformed the way gene regulation is
used in laboratory settings. So-called “gene-knockdown” (as opposed to gene-knockout,
when a gene is removed from the DNA sequence) is now a widely accepted laboratory
technique to study the function of genes in vitro and in vivo.
Gene regulation by RNAi is dependent on short pieces of double stranded RNA
(dsRNA) complementary to the target mRNA sequences (Davis et al., 2010). The RNA
molecules can be endogenous, transcribed from RNA-encoding genes to form stem-loop
structures which are exported to the cytoplasm and typically called micro RNA
(miRNAs). Exogenous RNAs that participate in the RNAi pathway can be the product of
a virus or laboratory applications. During laboratory manipulations, the dsRNA used is
sometimes called siRNA initially, although the distinction is rather insignificant at this
point.
Endogenous and exogenous interfering RNAs initiate the RNAi machinery once
they are present in the cell‟s cytoplasm. There, both types of RNAs are processed by an
endoribonuclease enzyme called Dicer. The result of Dicer‟s action is a short dsRNA
fragment, called a small interfering RNA, with a length of typically 20-25 nucleotides
and a 3‟ and 5‟ two or three-base overhang. Bioinformatic studies have indicated this
length reduces nonspecific interactions while increasing the specificity of target gene

knockdown (Qiu et al., 2005). After this point the endogenous and exogenous RNAi
pathways become indistinguishable from one another.
The appearance of siRNA in the cytoplasm activates the RNA-induced silencing
complex (RISC). This occurs via interaction between the short dsRNA and Argonaute,
the catalytic component of the RISC complex, which results in the separation of the RNA
strands into single stranded RNAs (Qiu et al., 2005). The complexation of RISC with the
single stranded RNA allows it to bind to mRNA with complementary sequences.
Consequently, cleavage of the mRNA occurs and it cannot be used as a template for
protein translation. Thus, the gene whose protein product was encoded by the
complementary mRNA is “knocked-down”.

siRNA DELIVERY
The delivery of siRNA in an in vitro experiment can be achieved in several
different ways (Davis, 2009). PEI-based reagents bypass situations where the cell
membrane must become more permeabilized than normal, because it can be endocytosed
through normal cellular processes. The cationic PEI polymer, together with negatively
charged siRNA, forms a complex molecule without a net charge. The complex is released
when the environment inside the endosome becomes acidic, protonating the siRNA and
causing electrorepulsion of the cationic polymer. Although the mechanisms for the
transport of the siRNA outside of the endosome are not clearly elucidated, hypotheses are
currently focusing on the disruption of the acidic environment inside the endosome,
which would normally form a lysosome, as a trigger for the endosome to dissociate and
release the siRNA into the cell.

In addition to the advantage of this delivery method over cell membrane
disruption methods, some groups have been able to favorably modify the PEI. These
modifications include adding a ligand to the terminus of the polymer so that it is targeted
to specific cell types (Davis, 2009). Incorporating drug delivery with the PEI-siRNA
complex is also an area of research currently being explored. These and other
developments will allow for specific cellular targeting mechanisms and have the potential
to be powerful new treatments.

AIMS
There are now many methods available for silencing specific proteins in vitro, and
previous unpublished research from our laboratory indicated a membrane permeabilizing
procedure was successful for in vitro silencing. However, it was important to find a
clinically relevant method for this silencing. The primary goal of this research was to
determine if a polyethylenimine-based protocol could be used to silence PARP-1,
MGMT, and combinations of both proteins. In order to complete the primary goal, it was
necessary to assess presence or absence of the genes of interest and establish gene
expression levels before and after silencing the proteins of interest.

METHODS

CELL CULTURE
Four human glioma cell lines were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). Cells were cultured in Minimum Essential Medium –
Eagles (MEME), purchased from the ATCC, and 10% Fetal Bovine Serum (FBS)
(Lonza, Basel, Switzerland) was added as a supplement for cell growth. All cell cultures
were grown in a humidified incubator at 37°C and 5% CO2 atmosphere. Cells flasks were
25 cm2 and cells were plated at 500,000 cells per flask in 10 mL complete media. Cell
cultures were maintained in the humidified incubator and passed when cell monolayers
reached 80-90% confluency. For transfer to a 96-well plate, cells were plated at 10,000
cells per well in 100 L complete media.
The LN-229 cell line (ATCC# CRL-2611) was isolated in 1979 from a
glioblastoma in the right frontal parieto-occipital complex of a 60-year old white woman
(Diserens AC, et al., 1981). Oncogene characterization has shown that this cell line has
mutated p53, wild type PTEN and deletions of p16 and p14ARF (Ishii et al., 1999). The
T98-G cell line (ATCC# CRL-1690) comes from a 61-year old Caucasian male
glioblastoma sample. Cytogenetic analysis of this cell line has shown hyperpentaploid
chromosome count with numerous structural alterations (Olopade et al., 1992). The U138MG cell line (ATCC# HTB-16) was acquired from grade IV glioblastoma in a 47
year old Caucasian male. This cell line also exhibits polyploidy, ranging from
hyperdiploid to pentaploid chromosomes (Olopade et al., 1992). The final cell line, U-

87MG (ATCC# HTB-14) was cultured from a grade IV glioblastoma in a Caucasian 44
year old female and usually exhibits hypoploidy (Beckman G, et al., 1971).

SILENCING
For siRNA transfection, the cationic polyethylenimine-based polymer regent
INTERFERin™ (Polyplus, New York, NY) was used. The protocol from the
manufacturer was used for all experiments, with a modification for a final concentration
of 10 nM siRNA in each treatment well. The PARP-1 siRNA used was obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and consisted of a pool of three human
target-specific 20-25 nucleotide siRNAs. The siRNA for Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and MGMT were obtained from Applied Biosystems/Ambion
(Austin, TX). All siRNAs were diluted to 10 M working solutions.
For the silencing protocol, 0.17 L of 10 M siRNA was mixed by pipetting with
50 L MEME, per well. Then, 0.75 L of INTERFERin™, per well, was added to the
siRNA solution. These solutions were made as master mixes and scaled by number of
treatment wells necessary. Once combined, the reagents were mixed immediately by
vortexing for 10 seconds. Following this, the siRNA treatment solution was incubated for
10 to 30 minutes at room temperature. During the incubation, the old media in the 96well plate was removed and replaced with 125 L of new, complete media. Finally, 50
L of the siRNA treatment solution was added to each well by experimental treatment
group.

RNA EXTRACTION
For RNA extraction from cell culture flasks, the cells were removed by gently
scraping and transferred by pipette to a 15 mL centrifuge tube. Cell pellets were formed
by centrifuging at 10,000 x g for 10 minutes and the supernatant was removed. Next, the
cells were resuspended in 5 mL sterile phosphate buffered saline (PBS), pH 7.4, to wash
away any remaining media. The cells were counted with a hemocytometer and an aliquot
representing 30,000 cells removed for RNA extraction. If necessary, the volume of cells
in PBS was increased to 300 L, or the cells were centrifuged in a 1.5 mL
microcentrifuge tube at 10,000 x g and subsequently resuspended to reduce the volume of
PBS to 300 L.
The following protocol for RNA extraction has been adapted from the
manufacturer‟s RNeasy Kit “Purification of cytoplasmic RNA from animal cells”
protocol (Qiagen, Valencia, CA). Briefly, 300 L of RLT buffer was added to the cells
and mixed thoroughly by pipetting. This solution was transferred to a QIA shredder and
centrifuged for 2 minutes at 10,000 x g. Then, 300 L of ethanol (96-100%) was added to
the lysate and this solution was transferred to an RNeasy spin column, which was
centrifuged at 10,000 x g for 15 seconds. The collector was replaced and 600 L RW1
buffer was added to the column and centrifuged for an additional 15 seconds at 10,000 x
g. Afterward, the collector was replaced and 400 L RPE buffer was added to the spin
column and centrifuged at 10,000 x g for 15 seconds. This was repeated once more, with
centrifugation at the same speed for 2 minutes. The column was then placed into a new
collector and the RNA was eluted by adding 45 L of nuclease free water and

centrifuging for 1 minute at 10,000 x g, and repeating once. The RNA in the collector
was then transferred to a labeled 1.5 mL microcentrifuge tube and stored at -80°C.
For RNA extraction from 96-well plates, the protocol differs slightly. Briefly, the
media was removed from the wells using a micropipettor, and 100 L RLT buffer was
added to each well. The wells were gently scraped with a micropipettor tip to ensure
maximal detachment of cells from the plate. The cells were collected in triplicate (groups
of three wells), so that the RNA extracted was from 30,000 cells. Thus, three wells‟
worth of cells and RLT buffer is added to each QIA shredder, resulting in a final volume
of approximately 300 L. After this step, the protocol was the same as previously
described for cell culture flasks.

REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION
End-point gene expression was verified using reverse-transcriptase polymerase
chain reactions (RT-PCR) at 24 hours after silencing treatment (48 hours after plating).
Control groups were plated for 48 hours before analysis. The Access RT-PCR System
(Promega, Madison, WI) was used according to their published protocol. Briefly, each
reaction mix contained the following: 9 L sterile water, 25 L AccessQuick™ Master
Mix (2X), 1 L AMV reverse transcriptase (5u), 5 L forward primer (10 M), 5 L
reverse primer (10 M), and 5 L of extracted RNA sample. The reverse transcription
and PCR amplification conditions were set as indicated in the manufacturer‟s “Standard
RT-PCR” protocol.
Custom primers were designed and purchased from Integrated DNA Technologies
(IDT, Coralville, IA) for MGMT and PARP-1. The MGMT primer sets had a forward

primer sequence of 5‟-AGGAGCAATGAGAGGCAATCCTGT-3‟, and a reverse
sequence of 5‟-AGGGCAGCGTTAGAGAAGGAAACA-3‟. The forward sequence for
the PARP-1 primer set was 5‟-TGCAAGAAATGCAGCGAGAGCATC-3‟, with a
reverse sequence of 5‟-TGGATGGTACCAGCGGTCAATCAT-3‟. Both primer sets had
melting temperatures of 60.3°C, with the exception of the PARP-1 forward primer, which
had a melting temperature of 60.2°C. Both of these primers were diluted to 10 M
working solutions.
A stock GAPDH primer set was also obtained from IDT. The forward sequence
for the GAPDH primer was 5‟-AAGGTCGGAGTCAACGGATTTGGT-3‟, and the
reverse primer sequence was 5‟-AGTGATGGCATGTGTGGTCAT-3‟. The melting
temperature of these primers was 60.5°C. These primers were also diluted to a working
solution of 10 M.

GEL ELECTROPHORESIS
Gels were prepared to be 2% agarose in 1X Tris/Borate/EDTA (TBE) buffer, with
1 L ethidium bromide per 100 mL TBE. The samples were prepared for loading by
adding 5 L of 10X loading dye (1/10 total sample volume). In each well, 15 L of the
sample was loaded. For the ladder, a 100 bp exACTGene PCR ladder (Fisher
BioReagents, USA) was used, with 10 L loaded as needed. Depending on the size of the
gel, electrophoresis run time was either 45 minutes (small) or 80 minutes (large), both at
100 volts for the duration of run time. Results were visualized under UV light, using
Kodak imaging software (Kodak, Rochester, NY).

QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION
Relative gene expression was quantified using real-time PCR (qRT-PCR) using
the Applied Biosystems StepOne 48-well block real-time PCR thermocycler (Foster City,
CA) with reagents from the same company. Baseline analysis was performed on cells that
had been plated for at least 24 hours. Pre-designed gene expression assays with FAM
labeling from Applied Biosystems specific for PARP-1 (Assay ID Hs00911379_g1),
MGMT (Assay ID Hs00172470_m1), and GAPDH (Assay ID Hs99999905_m1) were
used. The manufacturer‟s protocol for the TaqMan One-Step RT-PCR Master Mix
(Applied Biosystems) was used without any changes. Cycling began with a hold at 50⁰C
for two minutes, followed by 95⁰C for ten minutes and forty cycles of 15 seconds at
95⁰C, one minute at 60⁰C ran afterwards.

STATISTICAL ANALYSIS
Data from qRT-PCR reaction was analyzed using LineReg 2.0 software
provided by Applied Biosystems to establish relative quantity gene expression levels.
Prism 5 for Windows (GraphPad Software, San Diego, CA) was used to perform
statistical analysis on relative gene expression values. A one way ANOVA with a Tukey
post test was used for comparison. Significance was one asterisk (*) if p<0.05, two (**) if
p<0.01 and three (***) if p<0.001.

RESULTS

To verify the presence and activity or absence of each gene of interest, reverse
transcriptase PCR and subsequent gel electrophoresis were performed on mRNA
extracted from each cell line. The genes of interest were the endogenous control GAPDH,
and the two target genes PARP-1 and MGMT. As shown in Figure 1 (Appendix A), all
cell lines were positive for GAPDH mRNA. The presence of PARP-1 mRNA was readily
apparent in each of the four cell lines. Finally, MGMT mRNA was also determined to be
present, as evidenced by amplification in each of the cell lines.
After verifying the endogenous control and the presence of each of the genes of
interest, PARP-1 and MGMT, several silencing studies were undertaken. Figure 2 shows
the result from a 24 hour MGMT siRNA treatment using the INTERFERin™ protocol in
U-138 cells. The relative quantity of MGMT gene expression for U-138 cells treated with
MGMT siRNA for 24 hours was significantly reduced when compared to the untreated
U-138 control (P=0.0031). Decreased expression of MGMT after siRNA treatment was
also observed at 24 hours in the T-98 cell line (Figure 3). These results are representative
of what would be expected in the other two cell lines after 24 hour treatment with MGMT
siRNA.
The duration of the siRNA silencing was determined by assessing relative gene
expression quantity over several time points. As shown in Figure 3, MGMT silencing
was achieved in T-98 cells at three consecutive time points: 24 hours, 48 hours, and 72
hours. Relative to the untreated T-98 control, cells treated with MGMT siRNA showed

significantly decreased levels of MGMT expression (P=0.0008). However, at no time
point was the MGMT expression significantly different from another time point.
Baseline PARP-1 expression level for all four cell lines was established. The
relative quantity of PARP-1 was highest in the U-87 cell line (Figure 4). The lowest
PARP-1 gene expression level relative to the U-87 cell line was found in the U-138 cell
line. The other two cell lines, LN-229 and T-98, had much lower PARP-1 gene
expression levels than the U-87 cell line. These results agree with the RT-PCR results
shown in Figure 1, showing that PARP-1 is expressed in all four cell lines.
After establishing the presence and relative gene expression for PARP-1 in each
of the cell lines, the INTERFERin™ silencing protocol was used to silence PARP-1.
Figure 5 shows PARP-1 silencing at a single time point in the LN-229 cell line. The
PARP-1 gene expression in LN-229 cell treated with PARP-1 siRNA for 24 hours was
65% lower when compared to the untreated LN-229 control sample. Similar decreases in
PARP-1 gene expression levels relative to the untreated controls at the 24 hour time point
were found in the U-138 and T-98 cell lines.
PARP-1 silencing was shown to persist over multiple time points similar to the
MGMT silencing. Shown in Figure 6, PARP-1 silencing persisted in T-98 cells over three
consecutive time points: 24 hours, 48 hours, and 72 hours. Levels of PARP-1 gene
expression were significantly reduced (P=0.0003) relative to the untreated T-98 control
cells. From the 24 hour sample to the 72 hour sample, it appears the PARP-1 gene
expression continues to decrease relative to the untreated T-98 control. Finally at 72
hours the PARP-1 gene expression was virtually undetectable in the T-98 cells.

After demonstrating that both MGMT and PARP-1 could be silenced using
siRNA it was of interest to determine whether silencing of MGMT and PARP-1 could be
established concurrently in cells using the INTERFERin™ protocol. Gene expression of
MGMT after combination silencing is shown in Figure 7. Compared to the untreated U138 control, cells administered a treatment containing only MGMT siRNA showed
significantly (P=0.0002) diminished MGMT gene expression (Figure 7). For U-138 cells
treated with both MGMT and PARP-1 siRNA at the same time, a significant decrease in
MGMT gene expression was observed (P=0.0002). When compared to each other, single
MGMT siRNA treatment and combined MGMT and PARP-1 siRNA treated cells had
similarly decreased levels of MGMT expression, and did not differ significantly.
PARP-1 gene expression after combination silencing was assessed. The U-138
cells treated with only PARP-1 siRNA showed significantly lower levels of PARP-1 gene
expression when compared to the untreated control cells (Figure 8). When U-138 cells
were treated with both PARP-1 and MGMT siRNA, the PARP-1 gene expression level
was significantly reduced relative to the untreated U-138 control. The silencing
treatments, single or combined siRNAs, were not significantly different from one
another.

DISCUSSION

All four cell lines were positive for the endogenous control gene GAPDH, and its
mRNA product. This indicates that the gene was being actively transcribed into mRNA
and the extraction of RNA and amplification of mRNA was successful in all four cell
lines. Furthermore, each cell line was positive for mRNA from the PARP-1 gene (Figure
1). By using qRT-PCR, it was shown that the levels of PARP-1 gene expression between
the four cell lines varied (Figure 4). Finally, all cell lines were also shown to have mRNA
from the MGMT gene, indicating the MGMT gene was actively transcribed. This was
expected, as expression levels had previously been quantified by qRT-PCR for these four
cell lines (Davis, 2008).
Silencing was established for MGMT in two cell lines (Figures 2 and 3). The
levels of MGMT gene expression after silencing in the cell lines was significantly
reduced after MGMT siRNA treatment using the INTERFERin™ protocol. The reduction
in MGMT gene expression was quantifiably lower over three consecutive time points
when compared to the untreated control cells (Figure 3). No time points showed
significant differences in MGMT gene expression levels from one another. Similar results
for MGMT siRNA treatment would be expected in the other two cell lines, U-87 and
LN229.
It was also determined that PARP-1 could be silenced in three of the four cell
lines (Figures 5, 6, and 8). After PARP-1 siRNA treatment, the gene expression levels
were diminished to varying degrees between cell lines at the 24 hour time point (Figures
5, 6, and 8). Additionally, the reduction in PARP-1 gene expression levels appeared to be

stable over three time points in the T-98 cell line (Figure 6). As shown, in one instance,
PARP-1 gene expression was practically abolished at the 72 hour time point (Figure 6).
We assume PARP-1 siRNA treatment would produce similar results at 24 hours in the U87 cell line. Furthermore, similar results would be expected for the other three cell lines
(U-87, U-138, and LN-229) for gene expression levels after PARP-1 siRNA treatment at
three time points.
Together, these silencing time trials indicate that MGMT and PARP-1 siRNA
administered with the INTERFERin™ protocol can be used to silence the target genes of
interest. In addition, the relative quantity of gene expression shows significantly reduced
levels when cells are treated with either type of siRNA or in combination (Figures 7 and
8). The reduction in gene expression of both MGMT and PARP-1 targets was also stable
over three time points in the T-98 cell line (Figures 3 and 6). Moreover, the reduction in
expression of each target gene is comparable to the reduction in the other and this trend
continues at consecutive time points.
Furthermore, the INTERFERin™ protocol was used to successfully silence
PARP-1 and MGMT at the same time when administered as a combination treatment
(Figures 7 and 8). When compared to gene expression levels in untreated cells, the
combination treatment significantly reduced the relative quantity of gene expression of
both MGMT and PARP-1 targets. Additionally, the reduction in gene expression of either
target was comparable to the reduction observed when treating with either MGMT or
PARP-1 siRNA alone. Similar results would be expected in the other three cell lines,
especially in light of the reduction of gene expression after single siRNA treatment in the
T-98 and LN-229 cell lines.

Overall, the PEI-based INTERFERin™ silencing protocol was successful when
used for single siRNA applications or combination siRNA treatments. Silencing of either
MGMT or PARP-1 targets was successful in three of the four cell lines. Simultaneous
silencing of MGMT and PARP-1 was achieved in one of the four cell lines, and a
significant reduction in gene expression levels at three consecutive time points was
achieved in one of the four cell lines for single siRNA treatment.

CHAPTER THREE: TEMOZOLOMIDE

Temozolomide (TMZ) is currently the chemotherapy drug of choice for treating
newly diagnosed and refractory GBM (Stupp et al., 2005). A methylating agent, TMZ
(chemical structure: 3,4-dihydro-3-methyl-4-oxoimidaso[5,1-d]-1,2,3,5-tetrazine-8caboxamide) works by spontaneously hydrolyzing into the active intermediate 5-(3methyltriazen-1-yl)imidazole-4-carboxamide (MITC) during liver metabolism. The high
oral bioavailability and low bone marrow toxicity of TMZ makes it more favorable than
its structural analogue dacarbazine, with extensive tissue distribution and the ability to
cross the blood brain barrier (Newlands et al., 1997). Consequently, TMZ is used both as
a single agent and in combination with radiotherapy in the treatment of certain types of
cancer.

ACTION OF TEMOZOLOMIDE
The result of DNA methylation by TMZ is methyl adducts on three different
positions: N7-methylguanine (~70%), N3-methyladenine (~9%), and O6-methylguanine
(~5%) (Villano et al., 2009). At the O6-methylguanine position, antitumor activity
becomes inversely correlated to the expression levels of the DNA repair enzyme MGMT
(Yip et al., 2009). Resistance to TMZ occurs as MGMT is able to remove the DNA
methyl adduct and transfer it to an internal cysteine residue, which inactivates the MGMT
protein. Clinical studies investigating the methylation status of MGMT have corroborated
the relationship between benefit from TMZ and a methylated MGMT promoter as well as
the resistance to TMZ conferred by an active promoter for MGMT (Hegi et al., 2005).

The antitumor activity of the O6 –methylguanine position is the result of several
molecular processes. Since the methylated base appears to be an adenine to DNA
polymerases, the base is incorrectly paired with thymine, which the mismatch repair
(MMR) proteins MSH2 and MSH6 recognize and subsequently bind the mispairing
(Mojas et al., 2007). Once repair ensues, the MMR proteins reinsert a thymine base
instead of cytosine opposite the O6 –methylguanine and mismatch processing repeats
itself creating a futile cycle. Eventually the MMR cycling creates a single stranded break
in the DNA, later leading to doubles stranded breaks and apoptosis (Villano et al., 2009).

AIMS
TMZ has been established as the standard of care for malignancies in the central
nervous system (CNS), including GBM. In order to do additional studies it was
necessary to establish a consistent method for creating TMZ dose response curves in the
four cell lines of interest. The primary goal was to 1) determine the dose-dependent cell
response to temozolomide for each of the four cell lines; 2) determine the dose-dependent
response at three time points – 24, 48, and 72 hours; and finally, 3) determine the
effective concentration of TMZ that killed 50% of the cells for each cell line (EC50).
Additionally, a secondary goal was to establish a procedure for conducting TMZ dose
response curves that can be replicated.

METHODS

CELL CULTURE
The four human glioma cell lines obtained from the ATCC were cultured as
previously described. For the TMZ dose response assays, cells were transferred to a 96well plate, and plated at 5,000 cells per well in 100 L of complete media. To ensure the
accurate plating of cells, after centrifugation and during resuspension of the cells, a cell
strainer was used to ensure single cell suspension before plating in the 96-well plate. To
decrease pipetting errors, the cells were plated using a repeating pipettor. The plated cells
were then allowed to incubate for 24 hours before the initial TMZ treatment to ensure 5070% confluency within the experimental wells.

TEMOZOLOMIDE DOSE RESPONSE ASSAY
Temozolomide (TMZ) was purchased from Sigma-Aldrich (St. Louis, MO) and
carefully dissolved in 100% dimethyl sulfoxide (DMSO) to a concentration of 400 mM to
create a stock mixture. To ensure the maximal homogenization of TMZ and DMSO, the
mixture was vigorously vortexed and repeatedly mixed with a micropipettor. The stock
TMZ solution was subsequently used to make a master mix of 2000 M TMZ (0.05%
DMSO) in complete media (MEME + 10% FBS). The 2000 M TMZ master mix was
used to create a serial dilution of TMZ in complete media in the following
concentrations: 1600 M, 1200 M, 800 M, 640 M, 400 M, 320 M, 200 M, and
160 M. Each solution was vortexed for at least 10 seconds and repeatedly mixed with a

micropipettor to ensure homogenization. A control solution of 0.05% DMSO in complete
media was also prepared.
At 24 hours after plating, the original complete media on the cells was removed
using a multichannel micropipettor, being careful not to disturb the confluent cells. Next,
media containing the different treatment concentrations of TMZ, the DMSO control, or a
negative control of complete media was added to the cells. The time the cells were
without any media never exceeded 15 minutes. The final volume of treatment solutions in
the wells was 100 L. There were triplicate wells for each treatment group. All plates
were kept in an incubator at 37°C and 5% CO2 atmosphere for the duration of the
treatment time, with separate plates for each time point.

CELL VIABILITY ASSAY
The CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI)
was used to determine the number of viable cells after treatment. CellTiter-Glo® Buffer
was thawed and used to resuspend the CellTiter-Glo® Substrate. This mixture was
allowed to reach room temperature before use. Inversion of the reagents was sufficient to
form a homogenous solution, and then allowed to stand while the plates equilibrate to
room temperature. Equal amounts of CellTiter-Glo® Solution were added to the same
amount of cell culture medium within each experimental well, 100µL for this experiment.
An orbital shaker was used to mix the CellTiter-Glo® Solution completely with the
media already present in the well. After two minutes of mixing, the plate was incubated
at room temperature for 10 minutes. Finally, luminescence was determined using a

Turner Biosystems Modulus® Microplate Reader (Sunnyvale, CA) at 24, 48, or 72 hours
after treatment, with triplicate wells for each experimental group within a cell line.

STATISTICAL ANALYSIS
Luminescence values from the Cell-Titer Glo® protocol were converted to
survival percentages relative to the untreated control survival values. The doses of
temozolomide were transformed from micromolar values using the equation X=Log[X].
Prism 5 for Windows (GraphPad Software, San Diego, CA) was used to plot relative
survival values against the transformed temozolomide doses to generate a dose response
curves using a sigmoidal line of best fit. EC50 values were calculated from the best fit
curves and analyzed using a repeated measures ANOVA with a Tukey post test. Graphs
of EC50 values show the standard error of the mean (SEM). Significance was one asterisk
(*) if p<0.05, two (**) if p<0.01 and three (***) if p<0.001.

RESULTS

Dose dependent responses to temozolomide were characterized in all four cell
lines (LN-229, T-98, U-87, and U-138). The temozolomide dose response assay was
performed as described previously, and survival data was generated using the Cell-Titer
Glo® protocol and luminescence was recorded. Figure 9 shows the results from a 24 hour
treatment of four cell lines with increasing concentrations of TMZ (from untreated, 0 µM,
to the highest treatment group, 2000 µM). When analyzed, the null hypothesis that the
sigmoidal dose response curves would be the same for each cell line, was rejected
(P<0.0001). There were five outliers excluded from this analysis (3 from the U-87 cell
line and 2 from the U-138 cell line) leaving 103 samples.
Dose response curves were generated for each of the four experimental cells lines
at each time point: 24, 48, and 72 hours (Figures 10 and 11). There were no outliers in
either the 48 hour or the 72 hour analysis and statistical analysis indicated a significant
difference between each of the cell lines at 48 hours (P<0.0001). At 72 hours, there was
no difference in response (P=0.1508).
Dose response curves were also analyzed by cell line for each time point. For the
U-87 cell line, the curves were significantly different at each time point, P<0.0001, as
shown in Figure 12, and no outliers were found. The U-138 cell line also had
significantly different curves at each of the three time points (P=0.0264) with no outliers
reported (Figure 13). Figure 16 shows the dose response curves for the T-98 cell line,
which also had no outliers, however, the curves at different time points were not
significantly different from each other (P=0.2748). For the LN-229 cell line, depicted in

Figure 15, the curves were significantly different at each time point with no outliers
(P=0.0102).
From the TMZ dose response curves, the effective concentration (EC50) of TMZ
that killed 50% of the cells was determined for each cell line (Figure 16). The effective
concentration (EC50) of TMZ was determined for each cell line from the dose response
curves generated at 24 hours. Statistical analysis indicated that the EC50 values differed
significantly for all cell lines (P>0.0001). The U-87 median EC50 was 410.6 µM TMZ,
and had the most significantly different EC50 values when compared to the other cell
lines. The U-138 cell line median EC50 was 1135 µM TMZ. The T-98 cell line had a
median EC50 of 1364 µM TMZ, and the LN-229 cell line had a median EC50 of 736.9 µM
TMZ.
This analysis was also performed on the EC50 values at the 48 and 72 hour time
points (Figures 17 and 18, respectively). The ANOVA for the 48 hour experiment
indicated there were differences between the EC50 values for the four cell lines
(P>0.0001). At 48 hours, the U-87 median EC50 increased to 970.0 µM TMZ, and was
significantly different when compared to the T-98 cell lines and the LN-229 cell line but
not the U-138 cell line. The U-138 cell line median EC50 decreased to 860.0 µM TMZ,
and differed from both the T-98 and LN-229 cell lines. The T-98 cell line median EC50
was similar to the 24 hour value, at 1305 µM TMZ, and was significantly different from
the LN-229 cell line, whose median EC50 decreased at 48 hours to 543.7 µM TMZ.
The ANOVA performed on the EC50 values of the four cell lines at 72 hours
showed that there was no significant difference (P=0.0659) (Figure 18). The median EC50
value for the U-87 cell line was 859.5 µM TMZ, which was a slight decrease from the 48

hour value, but almost double the 24 hour value. For the U-138 cell line, the median EC50
value was 696.0 µM TMZ, which was a decrease from the 48 and 24 hour values. In the
T-98 cell line, the median EC50 value was 1048.0 µM TMZ, which was a slight decrease
from the 24 and 48 hour values. The LN-229 cell line had a median EC50 value of 811.9
µM TMZ at 72 hours, which was an increase from the 24 and 48 hour values. When the
T-98 cell line is excluded from the analysis, the differences are significant (P<0.0001).
The U-87 has a significantly higher EC50 than the U-138 and LN-229 cell lines and, the
U-138 cell line has a significantly lower EC50 value than the LN-229 cell line.
After comparing the cell lines to each other at all three time points, the cell lines
were analyzed by time point. Figure 19 shows the EC50 values for U-87 cells at 24, 48,
and 72 hours. The 24 hour EC50 differed significantly, but the 48 and 72 hour values were
not significantly different from each other. The U-138 cell line EC50 differed significantly
at all three time points (P<0.0001). The T-98 cell line had EC50 values that did not differ
(P=0.3262); (Figure 21). The LN-229 cell line had EC50 values that were significantly
different from one another (P=0.0053) (Figure 22). EC50 values differed at 24 and 48
hours and 48 and 72 hours, but did not differ when comparing 24 and 72 hour time
points.

DISCUSSION

Dose dependent responses to Temozolomide were characterized in all four cell
lines (LN-229, T-98, U-87, and U-138) (Figures 9, 10, and 11). In addition, a dose
response curve was created for each cell line at three different time points: 24, 48, and 72
hours (Figures 12, 13, and 14). Because the cell lines were derived from four different
tumors, it was not surprising that the response, as indicated by the dose response curves,
would be different for each cell line. There were significant differences in the dose
response curves at 24 and 48 hours, as expected (Figures 9 and 10). However at 72 hours,
the curves were not significantly different (Figure 11).
Using the dose response curves to TMZ, the effective concentration (EC50) values
were calculated for each cell line at three time points, 24, 48, and 72 hours (Figures 16,
17, and 18). When the EC50 value was compared between cell lines, it was expected that
the values would be different from each other at each time point. Like the dose response
curve analysis, the values were significantly different from each other at the 24 and 48
hour time points (Figures 16 and 17), but not at 72 hours (Figure 18).
There were several changes in EC50 values over time in the cell lines. At 24 hours,
the T-98 and U-138 cell lines had the highest EC50 values, followed by the LN-229 cell
line, and the U-87 line had the lowest EC50 (Figure 16). At 48 hours, the LN-229 had the
lowest EC50, the U-138 and U-87 cell lines have the next highest EC50 values
respectively, and the T-98 cell line again had the highest EC50 value (Figure 17). At 72
hours, the T-98 cell line appears to continue to have the highest EC50 value, but also has
the largest standard error (Figure 18). The U-138 cell line had the lowest EC50 value,

followed by the LN-229 line, which had an EC50 value very close to the U-87 cell line.
However, when the T-98 cell line is excluded from the analysis, the differences in EC50
values between the remaining cell lines is significant, with the U-87 having a
significantly higher EC50 than the U-138 and LN-229 cell lines. In addition, the U-138
cell line has a significantly lower EC50 value than the LN-229 cell line.
When the EC50 values are analyzed by cell line, some patterns appear. The U-138
EC50 values significantly decrease over the three time points (Figure 20). This pattern
also appears in the T-98 cell line; however, the differences were not significant,
presumably because of the large standard error in the 72 hour EC50 value (Figure 21). The
EC50 values for the LN-229 cell line significantly decrease from the 24 to 48 hour time
points, however, significantly increase from the 48 to the 72 hour time point (Figure 22).
The values at 24 and 72 hours for the LN-229 cell line were not significantly different
from one another. The opposite pattern appears in the U-87 cell line, where the 24 hour
EC50 value was significantly lower than the 48 and 72 hour values (Figure 19). Although
it appears that the EC50 value decreases from 48 to 72 hours, it was not significantly
different.
Overall, generating dose response curves for all of the cell lines at three different
time points was successful (Figures 12, 13, 14, and 15). It was also possible to calculate
EC50 values for the four cell lines at all time points (Figures 16, 17, and 18). With the
exception of the large variability in the 72 hour dose response curve for the T-98 cell line
(Figures 18 and 21), the curves and calculated EC50 values were significantly different
between cell lines, as expected. For most of the cell lines, the 72 hour EC 50 value was
lower than the 48 hour value (excepting the LN-229 cell line) (Figures 19, 20, 21, and

22). Finally, the procedure for conducting TMZ dose response curves appears to be
sufficiently established and is replicable according to the results from these twelve
experiments (Figures 9 through 22).

CHAPTER FOUR: PARP INHIBITION

PARP-1 inhibitors are instrumental in defining biological roles for PARP-1. They
are also emerging as effective cancer treatments. Three outcomes of PARP-1 activation
have been identified that have particular importance in drug development (Jagtap and
Szabo, 2005). First, as previously indicated, PARP-1 plays a role in the response to DNA
damage through recruitment of proteins for BER-mediated DNA repair. Additionally, in
situations of vast DNA damage, PARP-1 can deplete cellular energy pools by using
copious amounts of NAD+ to synthesize PAR, resulting in necrotic cell death. Third, as a
transcriptional coactivator of pro-inflammatory response genes, PARP-1 has been
implicated in the pathogenesis of inflammatory diseases. By inhibiting PARP-1 mediated
BER repair of DNA, conserving energy for apoptotic cell death and decreasing the
inflammatory response thereafter, PARP-1 inhibition as an adjuvant therapy in cancer
treatment could decrease adverse side effects and potentiate the effect of DNA damaging
chemotherapy agents (Curtin, 2007).
PARP-1 has now been studied under various conditions: inhibition using substrate
analogs, genetic disruption of the PARP-1 in knockout mice, a second generation of more
potent inhibitors and silencing using RNAi technology (Cheng et al., 2005; Shall and de
Murcia, 2000). The first PARP-1 inhibitors were based on the structure of its substrate,
NAD+, using substituted benzamides, most notably the classical PARP inhibitor
compound, 3-aminobenzamide (3-AB) (Curtin, 2005). Development of second generation
inhibitors identified three structural features necessary for increased potency which
resulted in PARP-1 inhibitors currently under testing in clinical trials, such as

AGO14699, INO-1001 and GPI 221016 (Ratnam and Low, 2007). Additionally, PARP-1
knockout mice and silencing technologies have been used to assess responses to ionizing
radiation and alkylating agents, which were the first observations of chemo- and radiosensitization when PARP-1 was absent (Shall and de Murcia, 2000). The results of these
studies provided the basis for proof of principle trials of PARP-1 inhibitors as an adjuvant
therapy, many of which have progressed to phase I and phase II clinical trials.

INHIBITION AS CANCER THERAPY
The role of PARP-1 in BER has some interesting implications in the repair of
damaged DNA in cells where homologous recombination is deficient. BRCA1 and
BRCA2 are tumor suppressor proteins that play an important role in repairing DSBs by
homologous recombination and, when mutated, are known to predispose breast and
ovarian cancers (Bryant et al., 2005). Loss of PARP-1 in cells gives rise to increased
sister chromatid exchange, which suggests the loss of BER results in the formation of
DNA lesions that are repaired by homologous recombination. PARP-1 inhibition in
BRCA2-deficient cells was shown to lead to spontaneous replication fork collapse and
trigger of homologous recombination when SSBs in DNA were detected, as evidenced by
more γ-H2AX foci and increased RAD51 foci (Bryant et al., 2005). Another group found
that using a PARP inhibitor significantly sensitized BRCA1- and BRCA2-deficient cells
to DNA damage by increasing the persistence of DNA lesions, and ultimately leading to
cell cycle arrest and subsequent apoptosis (Farmer et al., 2005).
These studies have identified a synthetic lethality, where BER deficiency or
homologous recombination alone does not cause tumor cell death (Tucker and Fields,

2003). Recent research indicates PARP inhibitors may be used as single agents in the
treatment of breast cancers with BRCA mutations (Bryant et al., 2005; Farmer et al.,
2005). Instead, by exploiting the defect in homologous recombination of BRCA1- and
BRCA2-deficient cells and inhibiting PARP-1 dependent BER of SSBs, tumor cells can
be specifically targeted for cell death (Bryant et al., 2005; Farmer et al., 2005). The
specificity for tumor cells occurs when they are homozygous for the loss of BRCA1 or
BRCA2, and normal cells retain homologous recombination (HR) ability because they
are heterozygous for these genes. By targeting a pathway that is not lethal in healthy
cells, PARP inhibition could be a highly specific treatment in BRCA-mutated breast
cancers and other cancers that show defects in homologous repair. In addition, this may
have an impact on other pathways that cause HR deficiency, such as loss of function of
check-point activating kinases ATM and ATR, RAD51, and others (Mangerich and
Burkle, 2011).
There is an alternate rationale for using PARP inhibitor in cancer treatment as
adjuvants to DNA-damaging chemotherapy drugs and radiotherapy. Classical cancer
therapies cause damage to DNA, which when left unrepaired, causes cell death.
Considering the previous discussion of PARP-1‟s involvement in DNA damage repair
pathways like BER, inhibition of PARP-1 likely contributes to the sensitization of tumor
cells to cytotoxic drugs and ionizing radiation. This principle is the basis for multiple
preclinical and clinical studies with PARP inhibitors in combination with classical
therapies (Mangerich and Burkle, 2011).

AIMS
Inhibition of PARP-1 has been associated with increased sensitivity to
chemotherapy agents like TMZ, and some studies have indicated PARP inhibition could
be a beneficial adjuvant in treating GBM (Horton et al., 2009; Tentori et al., 2005). The
primary goal was to compare the response to TMZ in GBM cell lines treated with either
1) single agent TMZ, 2) TMZ and the classical PARP inhibitor 3-aminobenzamide (3AB), or 3) single agent TMZ and PARP-1 siRNA treatment. A secondary goal was to
compare the response to adding a PARP inhibitor (3-AB) or silencing PARP-1 to
concurrent TMZ treatment.

METHODS

CELL CULTURE
The four human glioma cell lines obtained from the ATCC were cultured, as
previously described. For the PARP-1 inhibition (PARPi) dose response assays, cells
were transferred to a 96-well plate and plated at 5,000 cells per well. The total volume of
complete media in the wells was 100 L. As previously described, to increase accuracy, a
cell strainer was used to ensure they were in a single cell suspension before plating in the
96-well plate. A repeating pipettor was used to plate cells. Cells were then allowed to
incubate at 37°C and 5% CO2 atmosphere for 24 hours before the initial treatment to
ensure 50-70% confluency in the experimental wells. There were triplicate wells for each
treatment group.

PARP INHIBITION DOSE RESPONSE ASSAY
For this assay, the PARP inhibitor 3-aminobenzamide was purchased from
Sigma-Aldrich (St. Louis, MO). The powdered 3-AB was added directly to complete
media (MEME + 10% FBS) and this solution was warmed to room temperature and
manually stirred until dissolved. Complete media containing the PARP inhibitor 3-AB
will be referred to as PARPi media for the following assay. Fresh PARPi media was
made for each dose response assay, always with a final concentration of 33 µM 3-AB,
which is the IC50 for 3-AB where half of PARP activity is inhibited (Curtin, 2007).
Temozolomide (TMZ) was prepared as previously described. The stock TMZ
solution was used to make a master mix of 2000 M TMZ (0.05% DMSO) in PARPi

media and subsequently used to create a serial dilution of TMZ in PARPi media in the
following concentrations of TMZ: 1600 M, 1200 M, 800 M, 400 M, and 200 M.
Each solution was vortexed for at least 10 seconds and repeatedly mixed with a
micropipettor to ensure homogenization. A control solution of 0.05% DMSO in PARPi
complete media was also prepared.
Twenty-four hours after plating, the original complete media on the cells was
removed using a multichannel micropipettor, being careful to not disturb the confluent
cells. Next, media containing the different treatment concentrations of TMZ in PARPi
complete media, the DMSO control in PARPi media, and a negative control of complete
media was added to the cells. Cells were never without media for more than 15 minutes.
The final volume of treatment solutions in the wells was 100 L. All plates were kept in
an incubator at 37°C and 5% CO2 atmosphere for the duration of the treatment time, with
separate plates for each time point.

PARP-1 SILENCING DOSE RESPONSE ASSAY
For silencing treatment, PARP-1 siRNA was obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA) and consisted of a pool of three human targetspecific 20-25 nucleotide siRNAs. To transfect the cells with the PARP-1 siRNA,
INTERFERin™ (Polyplus, New York, NY) was used. For the silencing protocol, 0.17 L
of 10 M PARP-1 siRNA was mixed by pipetting with 50 L MEME per well. Then
0.75 L of INTERFERin™ per well was added to the PARP-1 siRNA solution. These
solutions were made as master mixes and the reagents were mixed by vortexing for 10
seconds immediately after being combined. Then the PARP-1 siRNA treatment solution

was incubated for 10 to 30 minutes at room temperature. During the incubation, the old
media in the 96-well plate was removed and replaced with 125 L of new, complete
media. Finally, 50 L of the siRNA treatment solution was added to each well by
experimental group. The protocol from the manufacturer was used for all experiments,
with the exception of a modification for a final concentration of 10 nM siRNA in each
treatment well.
Temozolomide (TMZ) was prepared as previously discussed. Briefly, the stock
TMZ solution was used to make a master mix of 2000 M TMZ (0.05% DMSO) in
complete media and subsequently used to create a serial dilution of TMZ in complete
media in the following concentrations of TMZ: 1600 M, 1200 M, 800 M, 400 M,
and 200 M. Each solution was vortexed for at least 10 seconds and repeatedly mixed
with a micropipettor to ensure homogenization. A control solution of 0.05% DMSO in
complete media was also prepared.
At 24 hours after the silencing treatment was applied, the siRNA media on the
cells was removed using a multichannel micropipettor, being careful to not disturb the
confluent cells. Next, media containing the different treatment concentrations of TMZ in
complete media, the DMSO control in media, and a negative control of complete media
was added to the cells. Cells were never without media for more than 15 minutes. The
final volume of treatment solutions in the wells was 100 L. All plates were kept in an
incubator at 37°C and 5% CO2 atmosphere for the duration of the treatment time, with
separate plates for each time point.

CELL VIABILITY ASSAY
As previously described, the CellTiter-Glo® Luminescent Cell Viability Assay
(Promega, Madison, WI) was used to determine the number of viable cells after
treatment. Luminescence was read using a Turner Biosystems Modulus® Microplate
Reader (Sunnyvale, CA) at 24, 48, or 72 hours after the TMZ containing treatment was
applied, with triplicate wells for each experimental group within a cell line.

STATISTICAL ANALYSIS
Luminescence values from the Cell-Titer Glo® protocol were converted to
survival percentages relative to the untreated control survival values. The doses of
temozolomide were transformed from micromolar values using the equation X=Log[X].
Prism 5 for Windows (GraphPad Software, San Diego, CA) was used to plot relative
survival values against the transformed temozolomide doses to generate a dose response
curves using a sigmoidal line of best fit. EC50 values were calculated from the best fit
curves and analyzed using a repeated measures ANOVA with a Tukey post test. Graphs
of EC50 values show the standard error of the mean (SEM). Significance was one asterisk
(*) if p<0.05, two (**) if p<0.01 and three (***) if p<0.001.

RESULTS

After defining the dose response curves for all four cell lines at each of three time
points (Chapter 3), the effect of adding 3-aminobenzamide, a PARP-1 inhibitor (PARPi)
or the effect of silencing PARP-1 (PARPsil) with the established temozolomide treatment
regimen was assessed. Figure 23 shows the results of a TMZ dose response curve with
the addition of a constant concentration of PARPi (33 µM 3-AB). Analysis confirms the
cell lines‟ curves showed significant differences at 72 hours (P<0.0001). Following
PARP-1 silencing, the TMZ dose response best fit curves for all four cell lines were
significantly different at 72 hours (P<0.0001) (Figure 24). In the PARP-1 silenced
treatments there were six outliers excluded from the analysis, four in the LN-229 cell line
and two in the T-98 cell line.
To perform a comparison on the efficacy of PARPi or PARP-1 silencing
(PARPsil) on TMZ sensitivity, each cell line was analyzed separately. The U-87 cell line
dose response curves at 72 hours for TMZ only, PARPi+TMZ, and PARPsil+TMZ are
shown in Figure 25. The best fit curves for each treatment group showed significant
differences (P=0.0189). Figure 26 shows a comparison of the EC50 values from the 72
hour treatments for the U-87 cell line. An ANOVA showed significant differences
(P=0.0012), between the TMZ only treatment (median EC50 of 859.5 µM TMZ) and the
PARPi+TMZ treatment (median EC50 of 604.2 µM TMZ). However, the TMZ only
treatment was not significantly different from the PARPsil+TMZ (median EC50 of 849.1

µM TMZ). Finally, the two PARP treatments, inhibition of PARP (PARPi+TMZ) and
silencing of PARP (PARPsil+TMZ) were highly significantly different from each other.
Analysis of the U-138 dose response curves to TMZ only, PARPi+TMZ, and
PARPsil+TMZ treatments showed significantly different curves (P=0.0487) (Figure 27).
The EC50 values for each treatment were calculated from the curves and compared by
ANOVA, which revealed there were significant differences between the treatments
(P=0.0006) (Figure 28). The TMZ only treatment (median EC50 of 696.0 µM TMZ)
showed a very highly significant difference from the PARPi+TMZ treatment (median
EC50 of 502.1 µM TMZ). The TMZ only treatment was not significantly different than
the PARPsil+TMZ (median EC50 of 655.5 µM TMZ). The two PARP treatments,
PARPi+TMZ and PARPsil+TMZ were highly significantly different from each other in
the U-138 cell line.
The dose response curves for the T-98 cell line were significantly different
(P<0.0001) from each other (Figure 29). Two outliers were excluded from the curve
analysis. In Figure 30, the EC50 values from each treatment group were compared, and
ANOVA analysis showed significance (P=0.0381). The TMZ only treatment had a
median EC50 of 1048.0, and was significantly different from the PARPsil+TMZ
treatment, which had a median EC50 of 423.2 µM TMZ. The PARPi+TMZ treatment
group was not significantly different from either of the other two treatments, and had a
median EC50 of 771.3 µM TMZ.
Although the dose response curves generated for each treatment were not
significantly different for the LN-229 cell line (Figure 31), an ANOVA performed on the
extrapolated EC50 values showed significance (P=0.0003). Figure 32 shows a comparison

of the EC50 values from each of the three groups, TMZ only, PARPi+TMZ, and
PARPsil+TMZ treatments. The TMZ only treatment had a median EC50 value of 811.9
µM TMZ and was very highly significantly different than the EC50 values for both PARP
treatments. In the PARP inhibition (PARPi+TMZ), the median EC50 was 1179.0 µM
TMZ, and was also very highly significantly different than the EC50 value in the PARP-1
silenced treatment (PARPsil+TMZ), which had a median EC50 of 453.2 µM TMZ.

DISCUSSION

Dose response assays to TMZ with the addition of a constant dose of the PARP
inhibitor (PARPi) 3-aminobenzamide were performed for each cell line at three different
time points: 24, 48, and 72 hours. Dose dependent response curves were characterized in
all four cell lines (LN-229, T-98, U-87, and U-138) at the 72 hour time point (Figure 23).
Because the cell lines are from four different tumors it was expected that the dose
response curves would vary between cell lines. This is what was observed when
PARPi+TMZ responses were compared (Figure 23).
Next, dose response assays to TMZ with the addition of a constant PARP-1
silencing were performed for each cell line at three different time points: 24, 48, and 72
hours. Dose dependent response curves to this treatment were characterized in all four
cell lines (LN-229, T-98, U-87, and U-138) at the 72 hour time point (Figure 24). Again,
because the cell lines are from four different tumors, the alternate hypothesis was that the
curves would be different for each cell line and the null hypothesis stated the cell lines
would have the same response. The null hypothesis was rejected, because the 72 hour
curves from PARPsil+TMZ treatment were significantly different from each other, as
expected (Figure 24).
The curves for treatment with the PARP inhibitor 3-aminobenzamide
(PARPi+TMZ) and addition of PARP-1 siRNA silencing (PARPsil+TMZ) were
compared to the TMZ only dose response at 72 hours for each cell line (Figures 25
through 32). The alternate hypothesis for this comparison was that each cell line would
have different curves for each treatment, in contrast to the null hypothesis which stated

each treatment would show the same curve. Excluding the LN-229 cell line, the curves
for the three treatments were significantly different for the remaining cell lines at the 72
hour time point and the null hypothesis was rejected. It was expected that the cell lines
would respond differently to TMZ only, PARPi+TMZ, and PARPsil+TMZ treatments.
The EC50 values for each of the experimental treatments were calculated from the
dose response curves and compared by cell line to the TMZ only control treatment. In the
U-87 and U-138 cell lines, the PARPi+TMZ treatment showed the most significant
decrease in the EC50 value or highest increase in sensitivity to TMZ (Figures 26 and 28).
Likewise, there was a slight decrease in EC50 value for the PARPsil+TMZ treatment for
both cell lines, but it was not significantly different from the TMZ only control. In both
U-87 and U-138 cell lines, the PARPi+TMZ treatment EC50 value was significantly
lower than the PARPsil+TMZ treatment. Thus, the addition of the PARP inhibitor
showed the highest increase in sensitivity to TMZ in the U-87 and U-138 cell lines, and it
was expected that manipulating PARP would show significant differences in the response
to TMZ.
In the other two cell lines, T-98 and LN-229, the PARPsil resulted in the highest
increase in sensitivity to TMZ (Figures 30 and 32). For the T-98 cell line, the
PARPi+TMZ treatment showed a decreased EC50, but was not significant. However, the
PARPsil+TMZ showed a significantly decreased EC50 value compared to the TMZ only
control. This indicates an increased sensitivity to TMZ in the silencing treatment for the
T-98 cell line (Figure 30). Accordingly, the LN-229 cell line showed a significantly
decreased EC50 value when the TMZ only control was compared to the PARPsil+TMZ
treatment, thus an increase in TMZ sensitivity (Figure 32). Unlike the other cell lines the

LN-229 cell line treated with PARPi+TMZ had a significantly increased EC50 compared
to the TMZ only control, showing decreased TMZ sensitivity. This was unexpected,
however other differences in sensitivity to TMZ when PARP was manipulated were
expected.
In conclusion, for two cell lines (U-87 and U-138), the addition of the PARP
inhibitor 3-aminobenzamide at a constant dose to TMZ treatment caused a significant
increase in sensitivity to TMZ (Figures 26 and 28). For the other two cell lines (T-98 and
LN-229), when PARP-1 was silenced with TMZ treatment, the TMZ sensitivity increased
significantly (Figures 30 and 21). Finally, with the exception of LN-229 PARPi+TMZ
treatment, the EC50 values decreased when PARP was manipulated by the addition of
either a PARP inhibitor or PARP-1 siRNA to TMZ treatment.

CHAPTER FIVE: COMBINATION STUDIES

Although TMZ can be used alone as monotherapy, or in addition to irradiation
therapy in the treatment of GBM, there are several indications that combination therapies
may be more effective in decreasing initial or acquired resistance to TMZ. As previously
discussed, the antitumor activity of the O6 –methylguanine position can be attenuated by
the presence of MGMT (Hegi et al., 2005). In addition, the participation of PARP-1 in
DNA damage repair pathways such as BER, contributes to a cancer cell‟s resistance to
therapy with DNA damaging agents like TMZ (Villano et al., 2009). Therefore, strategies
to target multiple resistance mediators may be an appropriate therapy for GBM.

STRATEGIES TO DECREASE RESISTANCE
As discussed, the cytotoxicity of TMZ is mainly mediated by the methyl adduct at
the O6 position, whereby unsuccessful cycles of MMR cause irreparable DSBs in the
DNA. When MGMT is present it is able to restore the integrity of the O6 position and
thus, resistance occurs. While there have been several studies that have investigated the
use of structural analogs such as O6 –Benzylguanine (O6 –BG) to deplete the cell‟s
MGMT suicide enzymes, it appears this may only be a transient inhibition and some
increases in systemic toxicity were found (Hegi et al., 2008). With the advent of delivery
agents that could support human use of siRNA, specific targeting of MGMT within a
limited area surrounding the tumor bed may be a suitable alternative to using additional
chemotherapy drugs.

Additionally, the other sites where TMZ adds methyl adducts, N7-methylguanine,
N3-methyladenine, comprise most (~80%) of the damage done to DNA (Villano et al.,
2009). These methylpurines are thought to be repaired through the BER pathway, and do
not contribute substantially to the antitumor activity of TMZ. However, studies have
shown that following TMZ treatment and PARP inhibition, these methylpurines persist
and there are increased levels of SSBs and DSBs in the DNA (Heacock et al., 2010). In
this way, PARP inhibition can attenuate resistance to TMZ, even in MMR-deficient cells,
as this has been shown in a glioma xenograft (Cheng et al., 2005). By restraining the
BER pathway, PARP inhibition could be a beneficial adjuvant to several types of
chemotherapy drugs.
Although there are several PARP inhibitors entering and currently being tested in
clinical trials, the addition of drugs to a strenuous chemotherapy and/or radiotherapy
regimen could result in multiple off target effects. Such as the case with the MGMT
inhibitor O6-BG, where quelling an enzyme that is responsible for reversing DNA
damage in normal cells, which can cause significant side effects, such as hematologic
toxicity (Hegi et al., 2008). However, as previously mentioned, by targeting PARP-1 (and
MGMT) using siRNA could be a fitting alternative to combining several types of
chemotherapy drugs.

SILENCING IN HUMANS
Progress toward the in vivo use of siRNAs has been exciting for multiple models
of disease. The first human clinical trial of synthetic siRNA was launched in 2004 in
patients suffering from blinding choroidal neovascularization and has been followed by

several additional clinical studies (Davis et al., 2010). The first clinical trial using a
targeted nanoparticle-delivery system in patients with solid cancers was conducted by
Davis et al. (Clinical Trial Registration Number NCT00689065). The novel delivery
system for the specific siRNAs was composed of a linear polymer conjugated to a
targeting ligand (a human transferrin protein ligand), and an additional hydrophilic
polyethylene glycol (PEG) polymer for stability in biological fluids. In this case, the
targeting ligand was specific for tumor cells overexpressing the transferrin receptor.
Conclusions from the phase I study indicated that RNAi can be stimulated in humans
using synthetic siRNA delivered with targeted nanoparticles (Davis et al., 2010).
There are several advantages to siRNA and the delivery system outlined above
(Davis, 2009). First, siRNA can be designed for any protein and can elicit an RNA
interference mechanism in humans. Second, the linear polymer is able to wrap naked
siRNA into nanoparticles based on the electrochemical attractions of these two molecules
and are small enough (50 to 70 nm) to be endocytosed into cells. Third, the stabilizing
polymer can be conjugated to a targeting ligand to bind specific cell surface receptors
(e.g. those that are overexpressed or mutated in certain cancers). Fourth, once
endocytosed, the siRNA is able to be released during the acidification of the endosome,
which initiates the dissembly of the nanoparticle and escape from the endosome. These
advantages came together in the development of CALAA-01, a two-vial formulation of
three components: the delivery components of a linear polymer and a PEG polymer with
the targeting ligand in the first vial, and the second vial containing the siRNA (Davis,
2009). This two vial delivery system, when combined, self-assembles into nanoparticles
and can be given via intravenous administration and was shown to localize in the targeted

area (Davis et al., 2010). These studies are promising and may soon lead to additional
targeted therapies.

AIMS
The literature indicates a strong correlation between MGMT activity and
increased resistance to TMZ. Multiple lines of reasoning support PARP inhibition
lending to increased sensitivity to TMZ. This study was designed to test cell response to
MGMT and PARP-1 inhibition in combination with TMZ treatment. The primary goal
was to compare the differences between response to 1) single agent TMZ, 2) MGMT
silencing with TMZ treatment, 3) double silencing using siRNA to MGMT and PARP-1
with concomitant TMZ, and 4) MGMT silencing with PARP-1 inhibition via 3-AB and
concomitant TMZ treatment in GBM cell lines. The secondary goal of this research was
to compare the differences between responses to all types of treatments investigated in
this thesis.

METHODS

CELL CULTURE
The four human glioma cell lines obtained from the ATCC were cultured as
previously described. For PARP-1 inhibition (PARPi) dose response assays, cells were
transferred to a 96-well plate and plated at 5,000 cells per well. The total volume of
complete media in the wells was 100 L. As described, to increase accuracy, a cell
strainer was used to ensure a single cell suspension before plating in the 96-well plate. A
repeating pipettor was used to plate cells. Cells were allowed to incubate at 37°C and 5%
CO2 atmosphere for 24 hours before the initial treatment to ensure 50-70% confluency
within the experimental wells. There were triplicate wells for each treatment group.

COMBINATION DOSE RESPONSE ASSAY
For silencing treatment, MGMT siRNA was obtained from Applied
Biosystems/Ambion (Austin, TX) and diluted to a 10 M working solution. To transfect
the cells with the MGMT siRNA, INTERFERin™ (Polyplus, New York, NY) was used.
For the silencing protocol, 0.17 L of 10 M MGMT siRNA was mixed by pipetting
with 50 L MEME, per well. Then, 0.75 L of INTERFERin™, per well, was added to
the PARP-1 siRNA solution. These solutions were made as master mixes and the
reagents were mixed by vortexing for 10 seconds immediately after being combined.
Following this, the MGMT siRNA treatment solution was incubated for 10 to 30 minutes
at room temperature. During the incubation, the old media in the 96-well plate was
removed and replaced with 125 L of new, complete media. Finally, 50 L of the siRNA

treatment solution was added to each well by experimental group. The protocol from the
manufacturer was used for all experiments, with the exception of a modification for a
final concentration of 10 nM siRNA in each treatment well.
As previously described, the PARP inhibitor, 3-aminobenzamide, was purchased
from Sigma-Aldrich (St. Louis, MO). Fresh PARPi media with a final concentration of
33 µM 3-AB was used. Temozolomide (TMZ) was prepared as previously discussed. The
stock TMZ solution was used to make a master mix of 2000 M TMZ (0.05% DMSO) in
PARPi media and subsequently used to create a serial dilution of TMZ in PARPi media
in the following concentrations of TMZ: 1600 M, 1200 M, 800 M, 400 M, and 200
M. Each solution was vortexed for at least 10 seconds and repeatedly mixed with a
micropipettor to ensure homogenization. A control solution of 0.05% DMSO in PARPi
complete media was also prepared.
At 24 hours after treatment, the siRNA containing media on the cells was
removed using a multichannel micropipettor and care was taken not to disturb the
confluent cells. Next, media containing the different treatment concentrations of TMZ in
PARPi complete media, the DMSO control in PARPi media, and a negative control of
complete media was added to the cells. Cells were never without media for more than 15
minutes. The final volume of treatment solutions in the wells was 100 L. All plates were
kept in an incubator at 37°C and 5% CO2 atmosphere for the duration of the treatment
time, with separate plates for each time point.

COMBINATION SILENCING DOSE RESPONSE ASSAY
For combination silencing treatment, PARP-1 siRNA (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) and MGMT siRNA (Applied Biosystems/Ambion, Austin, TX)
were diluted to a 10 M working solution. To transfect the cells with both siRNAs,
INTERFERin™ (Polyplus, New York, NY) was used. To keep the final concentration of
siRNA at 10 nM in each treatment well, 0.85 L of 10 M PARP-1 siRNA and 0.85 L
of 10 M MGMT siRNA, per well, was mixed by pipetting with 50 L MEME. Then,
0.75 L of INTERFERin™, per well, was added to the combined siRNA solution. These
solutions were made as master mixes and the reagents were vortexed for 10 seconds
immediately after being combined. Then the siRNA treatment solution was incubated for
10 to 30 minutes at room temperature. During the incubation, the old media in the 96well plate was removed and replaced with 125 L of new, complete media. Finally, 50
L of the siRNA treatment solution was added to each well by experimental group.
Temozolomide (TMZ) was prepared as previously discussed. Briefly, the stock
TMZ solution was used to make a master mix of 2000 M TMZ (0.05% DMSO) in
complete media and subsequently used to create a serial dilution of TMZ in complete
media in the following concentrations of TMZ: 1600 M, 1200 M, 800 M, 400 M,
and 200 M. Each solution was vortexed for at least 10 seconds and repeatedly mixed
with a micropipettor to ensure homogenization. A control solution of 0.05% DMSO in
complete media was also prepared.
At 24 hours after the silencing treatment was applied, the siRNA media on the
cells was removed using a multichannel micropipettor, and care was taken not to disturb
the confluent cells. Next, media containing the different treatment concentrations of TMZ

in complete media, the DMSO control in media, and a negative control of complete
media was added to the cells. Cells were never without media for more than 15 minutes.
The final volume of treatment solutions in the wells was 100 L. All plates were kept in
an incubator at 37°C and 5% CO2 atmosphere for the duration of the treatment time, with
separate plates for each time point.

CELL VIABILITY ASSAY
As previously described, the CellTiter-Glo® Luminescent Cell Viability Assay
(Promega, Madison, WI) was used to determine the number of viable cells after
treatment. Finally, luminescence was read using a Turner Biosystems Modulus®
Microplate Reader (Sunnyvale, CA) at 24, 48, or 72 hours after the TMZ containing
treatment was applied, with triplicate wells for each experimental group within a cell line.

STATISTICAL ANALYSIS
Luminescence values from the Cell-Titer Glo® protocol were converted to
survival percentages relative to the untreated control survival values. The doses of
temozolomide were transformed from micromolar values using the equation X=Log[X].
Prism 5 for Windows (GraphPad Software, San Diego, CA) was used to plot relative
survival values against the transformed temozolomide doses to generate a dose response
curves using a sigmoidal line of best fit. EC50 values were calculated from the best fit
curves and analyzed using a repeated measures ANOVA with a Tukey post test. Graphs
of EC50 values show the standard error of the mean (SEM). Significance was one asterisk
(*) if p<0.05, two (**) if p<0.01 and three (***) if p<0.001.

RESULTS

In order to characterize the changes in TMZ sensitivity between PARP
manipulation and other known GBM targets, the effect of silencing MGMT in several
combination treatments was assessed. Figure 33 shows curves generated from a 72 hour
dose response curve where MGMT was silenced (MGMTsil) in addition to TMZ
treatment. Analysis showed the curves for the four cell lines were significantly different
from one another (P=0.0005). During the analysis, no outliers were found. In addition,
the effect of silencing MGMT and PARP-1 at the same time (BOTHsil) to TMZ
treatment was assessed at 72 hours, as shown in Figure 34. Likewise, the curves for each
of the four cell lines were found to be significantly different from one another
(P<0.0001). In this analysis, one outlier (U-138) was excluded.
Additionally, the effect of PARP inhibition in combination with MGMT silencing
when added to TMZ treatment was assessed. For this treatment
(PARPi+MGMTsil+TMZ), a constant dose of 33 µM 3-aminobenzamide (PARPi) was
added to MGMT silencing. Then, increased doses of TMZ were administered as
previously described. The resulting curves for each of the four cell lines were
significantly different from each other (P=0.0051) (Figures 33, 34, and 35). There were
also no outliers found during this analysis.
Finally, each cell line was analyzed separately to determine changes in TMZ
sensitivity between the five different treatments. Briefly, for these analyses, the EC 50
values were extrapolated from the 72 hour dose response curves for the control (TMZ
only) and five treatment groups. The five treatment groups are as follows: PARPi+TMZ

(the addition of a constant dose of 33 µM 3-aminobenzamide to the different
concentrations of TMZ), PARPsil+TMZ (constant silencing of PARP-1 in addition to
TMZ), MGMTsil+TMZ (constant silencing of MGMT in addition to TMZ treatment),
BOTHsil+TMZ (silencing of PARP-1 and MGMT at the same time in addition to TMZ
treatment), and lastly, PARPi+MGMTsil+TMZ (the addition of a PARP inhibitor as
previously described, constant MGMT silencing, and TMZ treatment).
In the treatment comparison for the U-87 cell line shown in Figure 37, there were
significant differences (P<0.0001). When compared to the control TMZ only treatment,
the PARPi+MGMTsil+TMZ treatment showed a very highly significant decrease in EC50
value, followed closely by the PARPi+TMZ treatment (TMZ only median EC50 was
859.5 versus 599.2 and 604.2, respectively). The PARPi+TMZ and
PARPi+MGMTsil+TMZ treatments were not significantly different from each other.
However, the BOTHsil+TMZ treatment also showed a highly significantly decreased
EC50, with a median EC50 739.4 µM TMZ when compared to the TMZ only control.
Moreover, the BOTHsil+TMZ treatment was highly significantly different than the
PARPi+TMZ and PARPi+MGMTsil+TMZ treatments, showing an increased EC50 value.
The PARPsil+TMZ treatment was not significantly different than the TMZ only control.
Interestingly, the MGMTsil+TMZ treatment showed a very highly significantly increased
EC50 value (median 1027.0 µM TMZ).
The U-138 cell line treatment comparison showed two treatments with
significantly decreased EC50 values compared to the TMZ only control (P=0.0009)
(Figure 37). The PARPi+TMZ treatment showed the most significant decrease in EC50
value (median was 502.1 versus 696.0 µM TMZ for the TMZ only control). Although the

PARPsil and MGMTsil treatments did not show significant differences from the TMZ
only control, the BOTHsil treatment EC50 was significantly lower, with a median EC50 of
546.5 µM TMZ. Interestingly, the PARPi+MGMTsil+TMZ treatment showed a highly
significant increased EC50 (median of 901.5 µM TMZ) compared to the TMZ only
control. The difference between the PARPi+TMZ and BOTHsil+TMZ treatments was not
significant. However, the PARPi+TMZ treatment was significantly different than the
PARPsil treatment and the MGMTsil treatment. Accordingly, the
PARPi+MGMTsil+TMZ treatment was very highly significantly different than the other
treatment groups.
In the treatment comparison of the T-98 cell line, only two treatments were
significantly different, P=0.0040, than the control of TMZ only (Figure 38). The
PARPsil+TMZ showed the most significantly decreased EC50 value compared to the
TMZ only treatment (median EC50 values of 423.2 versus 1048.0 µM TMZ,
respectively). Compared to the TMZ only control, the PARPi+MGMTsil+TMZ treatment
showed the next most significantly decreased EC50 value, with a median EC50 of 556.0
µM TMZ. The other three treatments were not significantly different from the control of
TMZ only. Additionally, the only other significant difference was between the
PARPsil+TMZ and the MGMTsil+TMZ treatment groups, with the median EC50 for
MGMTsil+TMZ at 958.3 µM TMZ.
The LN-229 cell line had significant difference between the TMZ only control
and all other treatment groups (P<0.0001) (Figure 39). The PARPsil+TMZ and
PARPi+MGMTsil+TMZ treatment groups had very highly significantly decreased EC50
values, with median EC50 values of 453.2 and 574.1 µM TMZ, respectively, compared to

the TMZ only control median EC50 of 811.9 µM TMZ. These two treatment groups were
also significantly different from one another. Interestingly, the other three treatment
groups showed significantly increased EC50 values compared to the control. The
PARPi+TMZ and BOTHsil+TMZ showed the highest significantly increased EC50 values
(median EC50 values of 1179.0 and 1139.0 µM TMZ, respectively), followed by the
MGMTsil+TMZ treatment group, with a median EC50 of 1022.0 µM TMZ.

DISCUSSION

Dose response assays to TMZ with the addition of constant MGMT silencing
were performed for each cell line at three different time points: 24, 48, and 72 hours.
Dose dependent response curves were characterized in all four cell lines (LN-229, T-98,
U-87, and U-138) at the 72 hour time point (Figure 33). Because the cell lines are from
four different tumors, the alternate hypothesis was that the curves would be different for
each cell line and the null hypothesis stated the cell lines would have the same response.
The null hypothesis was rejected, as the 72 hour curves from MGMTsil+TMZ treatment
were significantly different from each other, which was the expected result.
Next, dose response assays to TMZ with the addition of constant MGMT and
PARP-1 silencing (BOTHsil) was performed for each cell line at three different time
points: 24, 48, and 72 hours. Dose dependent response curves to this treatment were
characterized in all four cell lines (LN-229, T-98, U-87, and U-138) at the 72 hour time
point (Figure 34). Again, because the cell lines are from four different tumors, the
alternate hypothesis was that the curves would be different for each cell line and the null
hypothesis stated the cell lines would have the same response. The null hypothesis was
rejected, and as expected the 72 hour curves from BOTHsil+TMZ treatment were
significantly different from each other.
The final treatment, the addition of a constant dose of the PARP inhibitor 3aminobenzamide and constant MGMT silencing (PARPi+MGMTsil+TMZ) to TMZ dose
response assays was performed in each of the cell lines. Dose dependent response curves
to this treatment were characterized in all four cell lines (LN-229, T-98, U-87, and U-

138) at the 72 hour time point (Figure 35). Accordingly, because the cell lines are from
four different tumors, the alternate hypothesis was that the curves would be different for
each cell line and the null hypothesis stated the cell lines would have the same response.
The null hypothesis was rejected, as the 72 hour curves from PARPi+MGMTsil+TMZ
treatment were significantly different from each other. This was the expected result for
this experiment.
The final analysis for each cell line was comparing the calculated EC50 values
from all five treatments to the TMZ only control (Figures 36, 37, 38, and 39). In the U-87
cell line, it was previously shown that the addition of PARPi to TMZ treatment
significantly increased TMZ sensitivity; but adding PARPsil to TMZ did not significantly
increase sensitivity (Figure 26). Silencing MGMT did not result in increased sensitivity
to TMZ. However, when MGMT and PARP-1 were silenced concomitantly, there was a
significant increase in sensitivity to TMZ. Nonetheless, the most significantly decreased
EC50 values were for the PARPi+TMZ and the PARPi+MGMTsil+TMZ treatments,
corresponding to the highest increases in TMZ sensitivity (Figure 36).
When the U-138 cell line was analyzed there were some unexpected results
(Figure 37). As previously shown, the PARPi+TMZ treatment showed a significant
decrease in EC50, thus an increased sensitivity to TMZ (Figure 28). Neither PARPsil nor
MGMTsil addition to TMZ treatments showed a significant difference in EC 50 values
when compared to the TMZ only control. When both targets were silenced (BOTHsil),
there was a significant decrease in EC50 value, which was not significantly different from
the PARPi+TMZ treatment, but nevertheless showed an increased sensitivity to TMZ
when both targets were silenced. Although the PARPi+TMZ treatment had already

shown a significant decrease in EC50, and the MGMTsil+TMZ showed an insignificant
decrease, when combined in the PARPi+MGMTsil+TMZ treatment, the EC50 value
significantly increased, displaying a decreased sensitivity to TMZ, which was unexpected
(Figure 37).
The T-98 cell line showed high variability in the TMZ only result, and had only
shown a significant increase in sensitivity to TMZ in the PARPsil+TMZ treatment group;
although the PARPi+TMZ treatment did show a decreased EC50 value (Figure 30). When
silenced alone, MGMTsil+TMZ did not show a significant decrease in EC50, but when
silenced concomitantly with PARP-1 (BOTHsil), there was a larger, though insignificant,
decrease in EC50. This was surprising because the PARPsil+TMZ shows the largest
significant decrease in EC50, or highest sensitivity to TMZ. Although PARP inhibition
alone in conjunction with TMZ did not produce a significant increase in sensitivity to
TMZ, when MGMT silencing was added (PARPi+MGMTsil+TMZ), TMZ was
significantly increased. As expected, none of the treatments showed an increase in EC50
values compared to the TMZ only control (Figure 38).
When the LN-229 cell line was analyzed, there were several unexpected results
(Figure 39). As previously shown, the LN-229 cell line showed the only significant
increase in EC50 value when PARP was manipulated, in the PARPi+TMZ treatment
group (Figure 32). Interestingly, when PARP inhibition was combined with MGMT
silencing (PARPi+MGMTsil+TMZ), the sensitivity to TMZ was significantly increased,
which was unexpected. However, the PARPsil+TMZ showed a significant decrease in
EC50 value compared to the PARPi+MGMTsil+TMZ, so it was still the most effective
treatment at increasing sensitivity to TMZ in the LN-229 cell line. Unexpectedly,

although there were significant decreases in EC50 when PARP-1 was silenced, when
PARP-1 silencing was combined with MGMT (BOTHsil) there was a significant increase
in EC50. Likewise, there was a significant increase in EC50 when only MGMT was
silenced (MGMTsil+TMZ). However, when PARP was inhibited with MGMT silencing
(PARPi+MGMTsil+TMZ), the EC50 was significantly decreased. Thus, the only
treatments that significantly increased TMZ sensitivity were PARPsil+TMZ and
PARPi+MGMTsil+TMZ and the other three treatments significantly decreased
sensitivity to TMZ (Figure 39).

SUMMARY & CONCLUSIONS

SILENCING WITH A PEI-BASED PROTOCOL
The primary aim of this thesis was to investigate methods for increasing
temozolomide sensitivity in glioblastoma multiforme. Once the presence of GAPDH, an
endogenous control, MGMT, and PARP-1 mRNA was confirmed (Figure 1), clinically
relevant silencing methods were employed to determine if MGMT and PARP-1 could be
knocked down in the glioblastoma cancer cell lines (Figures 2 through 8). Previous work
has indicated that MGMT and PARP-1 are able to be knocked down using siRNA (Aneja
et al., 2011; Hegi et al., 2005). Furthermore, the polyethylenimine-based protocol
INTERFERin™ has been shown to deliver bioactive siRNA into cells (Alshamsan et al.,
2009).Thus, it was expected this protocol would be able to reduce gene expression in the
human glioma cell lines, and this was true when one or both MGMT and PARP-1
siRNAs were applied at the same time using the polyethylenimine-based protocol.
Moreover, it was determined that the knockdown of MGMT and PARP-1 could be
sustained in the cells for 72 hours (Figures 3 and 6). Although there has been a large
amount of research on both MGMT and PARP-1 as targets in cancer therapy, it currently
appears studies with simultaneous silencing of MGMT and PARP-1 have not been
published (Hegi et al., 2008; Horton et al., 2009).

RESPONSE TO TEMOZOLOMIDE
Next, while TMZ has been established as the standard of care for GBM, in order
to do additional treatment studies it was necessary to establish a consistent method for

creating TMZ dose response curves in the four cell lines of interest (Stupp et al., 2005).
Dose dependent TMZ responses were observed and characterized in all four cell lines at
three different time points (Figures 9 through 22). Although there was a larger amount of
variability in the T-98 cell line at 72 hours (Figure 21), the procedure for generating the
curves was very consistent between cell lines and is able to be replicated (Figures 9
through 22). Furthermore, the effective concentration (EC50) of TMZ that killed 50% of
the cells for each cell line was calculated from the dose response curves and at each time
point (Figures 17 through 22).
The cell lines are from four different tumors, thus, it was expected the response to
TMZ would be different in each line when the EC50 values were compared. Furthermore,
a variable response to TMZ between the different cell lines had been previously observed
(Davis, 2008). The variability between cell lines was true for the 24 and 48 hour time
points, but not for the 72 hour time point (Figures 17, 18 and 19). When the EC 50 values
were analyzed within cell lines by time point, some patterns appear (Figures 19, 20, 21,
and 22). The U-138 EC50 values significantly decrease over the three time points (Figure
20). This pattern also appears in the T-98 cell line; however, the differences were not
significant, presumably because of the large variability in the 72 hour EC 50 value (Figure
21). The EC50 values for the LN-229 cell line significantly decrease from the 24 to 48
hour time points, however, significantly increase from the 48 to the 72 hour time point
(Figure 22). But, the values at 24 and 72 hours for the LN-229 cell line were not
significantly different from one another. The opposite pattern appears in the U-87 cell
line, where the 24 hour EC50 value was significantly lower than the 48 and 72 hour values

(Figure19). Although it appears that the EC50 value decreases from 48 to 72 hours, it was
not significantly different.
Generating dose response curves for all of the cell lines at three different time
points was successful (Figures 9 through 15). When compared to results from a previous
study, the EC50 values from these experiments were higher for three of the four cell lines
(Davis, 2008). For the U-87, T-98, and LN-229 cell lines, the EC50 was an average of
442.0 µM higher (range of 414.67 to 469.73 µM) than previously reported, but the U-138
cell line was 258.6 µM lower than previously reported (Davis, 2008). For most of the cell
lines, the 72 hour EC50 value was lower than the 48 hour value (excepting the LN-229
cell line, where the 72 hour value was similar to the 24 hour value). Since this pattern
appeared to be the most constant, the manipulations of PARP-1 and MGMT were
analyzed at 72 hours. Moreover, previous work indicated 72 hours of TMZ exposure was
optimal to induce cell death (Davis, 2008). Finally, the procedure for conducting TMZ
dose response curves appears to be sufficiently established and is replicable as shown for
the twelve experiments in Figures 9 through 22.
Considering the expression of MGMT as previously reported (Davis, 2008), the
results found in this study agree with the role of MGMT as a TMZ resistance factor in
GBM (Hegi et al., 2008; Liu et al., 2009b). The T-98 cell line, which has the highest
MGMT expression relative to the other three cell lines, has the highest EC50 value
indicating it was the least sensitive to TMZ treatment (Figures 16, 17, and 18). In the U138 cell line, which has the next highest relative MGMT expression, had the next highest
EC50 value at 24 hours (Figure 16), however by 72 hours the EC50 had decreased
significantly (Figure 20). The U-87 cell line, which had minimal MGMT expression

relative to the other cell lines had the lowest EC50 at 24 hours indicated the most
sensitivity to TMZ (Figure 16), but by 72 hours had an EC50 value higher than U-138
cells (Figure 18). The LN-229 cell line had the lowest relative amount of MGMT
expression, and was the most sensitive of the cell lines to TMZ at 48 hours (Figure 17)
but had a higher EC50 than the U-138 cell line at 72 hours (Figure 18). The agreement
between MGMT expression and TMZ showed similar variability in previous work to the
results presented herein (Davis, 2008). However, MGMT expression is not the only
determinant in sensitivity to TMZ, and considering the role that MMR plays in initiating
the cytotoxic SSBs in DNA, the literature indicates the functional status of these
additional pathways plays a significant role (Johannessen et al., 2008; Villano et al.,
2009).

PARP MANIPULATION

Because inhibition of PARP-1 has been associated with increased sensitivity to
chemotherapy agents like TMZ, the effect of PARP-1 inhibition and PARP-1 siRNA
treatment were explored (Curtin, 2005; Mangerich and Burkle, 2011). Dose dependent
TMZ responses with the addition of either a PARP inhibitor (33 µM 3-aminobenzamide)
or PARP-1 siRNA treatment were observed and characterized in all four cell lines at the
72 hour time point (Figures 23 and 24). The curves for treatment with the PARP inhibitor
3-aminobenzamide (PARPi+TMZ) and addition of PARP-1 siRNA silencing
(PARPsil+TMZ) were compared to the TMZ only dose response at 72 hours for each cell
line (Figures 25, 27, 29, and 31). Based on the functions of PARP-1 in BER, and
specifically in repairing damage induced by alkylating agents, it was expected the

addition of PARP-1 siRNA or the inhibitor 3-AB would cause the response to TMZ to
change from the TMZ only baseline (Heacock et al., 2010; Liu et al., 2009a). Excluding
the LN-229 cell line, the curves for the three treatments were significantly different for
the remaining cell lines at the 72 hour time point (Figures 23 and 24), as expected.
Considering the previous discussion of the single agent TMZ response results, it
remained expected that the cell lines should have different responses from one another
because they are from different tumors, in addition to variations in the response between
different treatments for a cell line (Chen et al., 2007; Hegi et al., 2005).
The effective concentration (EC50) of TMZ that killed 50% of the cells for each
cell line was calculated from the dose response curves for the PARP manipulation
treatments (Figures 26, 28, 30, and 32). The expectation was that the response to PARP
manipulation would be an increase in TMZ sensitivity, thus a decrease in the EC50 from
the 72 hour TMZ only response (Tentori et al., 2006; Tentori and Graziani, 2009).
Accordingly, the addition of the PARP inhibitor showed the highest increase in
sensitivity to TMZ in the U-87 and U-138 cell lines (Figures 26 and 28). In the other two
cell lines, T-98 and LN-229, the PARP-1 siRNA treatment showed the highest increase in
sensitivity to TMZ (Figures 30 and 32). With the exception of the LN-229 PARPi+TMZ
treatment, the EC50 values decreased when PARP was manipulated by the addition of
either a PARP inhibitor or PARP-1 siRNA to TMZ treatment.
The PARP inhibitor used for this assay was 3-aminobenzamide, which mimics the
normal substrate of PARP, NAD+ (Curtin, 2005; D'Amours et al., 1999; Ratnam and
Low, 2007). Although suitable for experimental applications, clinical inhibitors have
increased specificity and other properties making them more tolerable in a clinical setting

(Ratnam and Low, 2007). Additionally, in this assay 3-AB was used at a single
concentration of 33 µM, which is the IC50, or dose where half of the PARP activity is
inhibited and we assumed this IC50 was the same for our cell lines (Jagtap and Szabo,
2005). Based on the silencing studies of PARP-1 silencing with the PEI-based protocol,
the levels of PARP-1 were drastically reduced (Figures 5, 6, and 8) after siRNA
treatment. It would be pertinent to test the amount of PARP activity after treatment with
3-AB or PARP-1 siRNA, however, without that information, it is still likely that PARP-1
siRNA would have had a greater effect than 3-AB because of its specificity for the
PARP-1 mRNA. This was true in the T-98 and LN-229 cell lines (Figures 30 and 32), but
not in the U-87 and U-138 cell lines (Figures 26 and 28). Some research suggests
glioblastoma cells can modulate the transport of drugs and other extracellular factors
across their membrane and use this to mediate resistance to temozolomide (Le Calve et
al., 2010). This may explain some of the differences in response to PARP manipulation
treatment between these cell lines, as well as some of the unexpected results in the
combination treatments discussed later.

COMBINED MANIPULATION

The literature shows a strong correlation between MGMT activity and increased
resistance to TMZ, so silencing studies were done to examine the effect of MGMT
siRNA and combination MGMT and PARP-1 siRNA (BOTHsil) treatments (Hegi et al.,
2005; Hegi et al., 2008). For both of these treatments, dose dependent response curves
were characterized in all four cell lines at 72 hours (Figures 33, 34, and 35). Again,
because the cell lines were derived from different tumors, it was expected that the

response would be different to each treatment for every cell line. This was confirmed for
the MGMTsil treatment as well as the BOTHsil treatment. Moreover, it was expected
MGMTsil treatment would increase sensitivity in the cell lines based on previous work
(Davis, 2008). In light of the functions of MGMT and PARP-1 and studies examining
their relationship, it was expected this treatment would increase sensitivity to TMZ more
than either MGMTsil or PARPsil would (Hegi et al., 2008; Liu et al., 2009b;
Madhusudan and Middleton, 2005).
In the two cell lines that had previously responded to PARP-1 silencing treatment
(T-98 and LN-229; Figures 30 and 32), sensitivity to TMZ did not increase for MGMTsil
or BOTHsil (Figures 38 and 39). In the T-98 cell line, PARPsil treatment remained more
effective than either of the other silencing treatments. In fact, for both MGMTsil and
BOTHsil treatments in the LN-229 cell line, sensitivity to TMZ unexpectedly decreased
significantly (Figure 39). Likewise, MGMTsil treatment unexpectedly decreased
sensitivity in the U-87 cell line (Figure 36); but BOTHsil treatment did significantly
increase TMZ sensitivity. Similarly, the BOTHsil treatment significantly increased TMZ
sensitivity in the U-138 cell line, but the MGMTsil treatment did not have a significant
effect (Figure 37). Unlike previous work, MGMTsil was not effective in increasing TMZ
sensitivity (Davis, 2008). Furthermore, this is not what has been found in the literature
(Hegi et al., 2005). It is promising that the BOTHsil treatment worked for the U-87 and
U-138 cell lines to increase TMZ sensitivity, and this type of simultaneous silencing has
not been reported in the literature.
Thus, in no instance did MGMTsil treatment contribute to increasing sensitivity to
TMZ, rather, in two instances it decreased TMZ sensitivity (Figures 36 through 39).

These results are not supported by the literature or previous findings (Davis, 2008; Hegi,
2008). Likewise, in two cell lines, the BOTHsil treatment unexpectedly either decreased
TMZ sensitivity or had no effect on TMZ sensitivity (Figures 36 and 39). Although this
isn‟t specifically supported or unsupported by findings in the literature, based on
functional interactions and single silencing the literature supports the idea that combined
silencing of MGMT and PARP-1 would increase TMZ sensitivity (Hegi et al., 2005;
Tentori et al., 2010). However, BOTHsil treatment was able to significantly increase
TMZ sensitivity in the other two cell lines Figures 37 and 38), both of which had
previously had insignificant responses to silencing treatments or a decrease in TMZ
sensitivity. Increased sensitivity to TMZ was the expected response to combination
silencing; however consider the response to singular silencing it was surprising.
The other combination treatment, adding a constant dose of the PARP inhibitor 3aminobenzamide and constant MGMT silencing to TMZ dose response assays was
performed in each of the cell lines (Figures 36 through 39). Dose dependent response
curves to this treatment were characterized in all four cell lines (LN-229, T-98, U-87, and
U-138) at the 72 hour time point (Figure 35). Accordingly, because the cell lines are from
four different tumors, it was expected that the curves would be different for each cell line.
As expected, the 72 hour curves from PARPi+MGMTsil+TMZ treatment showed
significantly differences between them. Furthermore, the combination treatment of
PARPi+MGMTsil+TMZ was able to significantly increase TMZ sensitivity in three of
the four cell lines (Figures 36, 38, and 39). Unexpectedly, in the U-138 cell line, TMZ
sensitivity was significantly increased (Figure 37). As discussed with the BOTHsil
groups, there wasn‟t an indication from the literature that any of the cell lines would

respond with decreased sensitivity to a treatment targeting MGMT and PARP
simultaneously (Hegi et al., 2005; Tentori et al., 2010). However, it is encouraging that
three of the four cell lines, including the cell line most refractory to TMZ treatment in the
literature and in previous studies (T-98) showed an increased sensitivity to TMZ when
treated with this combination treatment (Figure 38). Compared to the BOTHsil treatment,
using the PARP inhibitor with MGMT silencing was more effective in decreasing the
EC50 of the three cell lines that responded to this treatment. This suggests that some of
the nonspecific effects of 3-aminobenzamide on PARP-2 could be responsible for
enhancing TMZ sensitivity in these cell lines (Curtin, 2007; Curtin, 2005).

VARIABLE RESPONSES BY CELL LINE

In the U-87 cell line, the response to silencing treatment was variable (Figure 36).
The specific targeting of PARP-1 with siRNA did not significantly change the TMZ
sensitivity, however, when MGMT was targeted, TMZ sensitivity decreased. This finding
is supported in the literature (Hegi et al., 2005). Because the U-87 cell line had the
highest PARP-1 gene expression relative to the other cell lines, it is possible that PARPsil
treatment was unable to decrease PARP-1 expression enough to alter TMZ sensitivity.
Further studies examining silencing of PARP-1 in the U-87 cells would need to be done
to validate this claim. It is promising that when both MGMT and PARP-1 were targeted
with siRNA in the BOTHsil treatment, TMZ sensitivity was significantly increased,
showing some synergy between these two targets. The most effective treatments in the U87 cell line were with the PARP inhibitor alone or in combination with MGMT silencing
(Figure 36). It is possible that the PARP inhibitor was more effective than PARPsil

treatment at modulating the activity of PARP-1 in the U-87 cells, and thus had a larger
effect. Again, assessing the level of gene expression after silencing and activity of PARP1 in these cells would be an appropriate future study. In addition, the PARP inhibitor may
be having an effect on PARP-2 activity as well (Curtin, 2007). In the combination
treatment, it is questionable whether the insignificant, however slight, increase in
sensitivity compared to the PARPi+TMZ treatment is due to the addition of MGMT
silencing in light of the other MGMT silencing results and because the U-87 cell line has
low levels of MGMT gene expression (Davis, 2008). Silencing studies looking at the
expression of MGMT before and after siRNA treatment would shed light on these results.
The U-138 cell line also had some variable responses to the experimental
treatments (Figure 37). When PARP-1 and MGMT were silenced alone there was not a
significant change in TMZ sensitivity; but, when they were silenced in combination, the
sensitivity to TMZ significantly increased. In light of the expression levels of PARP-1
relative to the other cell lines, it may not be surprising that PARPsil treatment did not
have a significant effect; however, it was surprising that this cell line expresses the
second highest amount of MGMT and did not show a change in sensitivity to TMZ with
MGMTsil treatment. This is supported by previous work silencing MGMT in the U-138
cell line (Davis, 2008). However, the significant change in TMZ sensitivity in BOTHsil
treatment suggests a synergy between PARP-1 and MGMT, where silencing both targets
is able to increase TMZ sensitivity and this is expected based on the literature (Tentori et
al., 2008; Tentori et al., 2010). The treatment that most significantly increased sensitivity
to TMZ in the U-138 cell line was PARPi (Figure 37). In light of the PARPsil treatment,
it suggests that the more significant effect of the PARPi treatment could be due to some

off target effects, such as inhibiting PARP-2, which has related DNA repair functions as
previously discussed (Tentori and Graziani, 2005). Unexpectedly, the combination
treatment with inhibition of PARP and MGMT silencing showed a significant decrease in
TMZ sensitivity. Since this cell line had high MGMT and should have responded to
MGMTsil treatment, and previously responded positively to PARPi treatment, it is
possible some alternate form of DNA repair became more favorable, such as HR, which
would not be inhibited by MGMT or PARP-1 silencing or PARP inhibition. Testing the
activity of PARP after inhibition with 3-AB in the U-138 cell lines, could shed light on
these results.
When the treatments were compared in the T-98 cell line, there were no instances
where TMZ sensitivity was significantly decreased, as expected (Figure 38). As
previously discussed, there were no significant differences when MGMT was silenced
alone or in combination with PARP-1 silencing. Previous work showed that T-98 cells
had high MGMT expression and they did not show an increase in sensitivity with MGMT
silencing, however, this may have been due to problems with silencing (Davis, 2008).
Silencing PARP-1 alone did have a significant effect on TMZ sensitivity, suggesting this
could be a more important target than MGMT in this cell line. Because this cell line also
had relatively high levels of PARP-1 expression, it was expected that silencing PARP-1
would change the response to TMZ, however, this was not supported in the BOTHsil
treatment. Although PARP inhibition alone and MGMT silencing alone did not produce a
significant difference in sensitivity, when combined in the PARPi+MGMTsil+TMZ
treatment, TMZ sensitivity significantly increased (Figure 38). Considering silencing
MGMT did not previously have an effect on TMZ sensitivity, it is possible that when

combined with the PARP inhibitor, with its likely off target PARP-2 inhibitor effects, a
synergy between the targets occurred to increase TMZ sensitivity (Tentori et al., 2010). It
is promising that targeting PARP in the T-98 cell line was able to increase sensitivity to
TMZ, and this may be independent of the high MGMT expression in this cell line.
The LN-229 cell line had several instances where TMZ sensitivity does not
appear congruent between treatments (Figure 39). Given that the LN-229 cell line had
little PARP-1 expression relative to the other cell lines, and virtually undetectable
MGMT expression, it was unexpected that all of the treatments significantly changed
TMZ sensitivity (Horton et al., 2009; Liu et al., 2009b). When MGMT was silenced
alone, or in combination with PARP-1, the cell line became more resistant to TMZ
treatment, which was unexpected based on the expression of these two proteins in the
LN-229 cell line and the literature (Liu et al., 2009a; Tentori and Graziani, 2009; Villano
et al., 2009). Likewise, with PARPi treatment, sensitivity to TMZ decreased, which is not
supported by the literature, and especially in light of the off target effects of 3-AB it is an
unexpected result (Goellner et al., 2011). Although MGMTsil treatment was not expected
to have an effect, considering the lack of MGMT expression, when combined with
PARPi treatment, which didn‟t have an effect alone, there was a favorable change in
TMZ sensitivity (Figure 38). Finally, when PARP-1 was silenced alone, there was a
significant increase in TMZ sensitivity, suggesting that abolishing the small amount of
PARP-1 in the cell line was able to contribute to TMZ sensitivity. It is likely there are
several other pathways contributing to the unexpected results in the LN-229 cell line that
have not been investigated here.

Overall, the cell lines had variable responses to the different PARP-1 and MGMT
treatments and there was not a specific pattern between them. In the U-87 and U-138 cell
lines, the addition of a PARP inhibitor appears to be the most effective treatment at
increasing TMZ sensitivity (Figure 36 and 37). For the T-98 and LN-229 cell lines,
PARP-1 silencing was the most effective treatment (Figure 38 and 39). Although in two
cell lines (U-87 and U-138) BOTHsil treatment was able to increase TMZ sensitivity,
silencing either PARP-1 or MGMT alone in those lines was not an effective treatment. In
contrast, the T-98, LN-229, and U-87 cell lines responded to the combination treatment
of PARPi+MGMTsil+TMZ with increased sensitivity to TMZ. Finally, only the T-98 cell
line responded as expected, with no treatment causing a decrease in TMZ sensitivity
(Goellner et al., 2011; Tentori et al., 2010).

CONCLUSIONS AND FUTURE DIRECTIONS
Comparisons of all five treatments were done to find the most effective method
for increasing the sensitivity to TMZ in the GBM cell lines (Figures 36 though 39).
Overall, based on evidence from the literature, there was no indication that any of the
experimental treatments would decrease TMZ sensitivity in the cell lines. It has been
previously shown that MGMT silencing should increase TMZ sensitivity (Hegi et al.,
2005; Hegi et al., 2008). This was supported by previous wok silencing MGMT in these
cell lines (Davis, 2008). Additionally, manipulating PARP-1 by small molecule
inhibition or specific silencing was expected to have an effect on TMZ sensitivity
(Heacock et al., 2010; Mangerich and Burkle, 2011; Maxmen, 2010). In this study, it is

likely that the inhibition of PARP-2 by 3-AB contributed to some of the PARPi
treatments' effects.
In order to do further analysis of the results presented in this study, the activity of
PARP-1 after treatment with siRNA and 3-AB should be assessed to determine whether
the treatments are having the sought after effect inside the cells. Furthermore, it would be
pertinent to test PARP inhibitors that are more specific for PARP-1 to compare to the
results from 3-AB, such as some of the PARP inhibitor drugs currently in clinical trials,
e.g. Olaparib or Iniparib (Curtin, 2007; Mangerich and Burkle, 2011; Olopade et al.,
2008). These studies would help to confirm whether nonspecific effects inhibiting PARP2 were affecting changes in sensitivity to TMZ in the cell lines. Finally, a functional
analysis of the activity of alternate DNA repair mechanisms like HR in these cell lines
may be able to shed light on why the manipulation of PARP alone was able to increase
sensitivity more than combined MGMT and PARP manipulation (Bryant et al., 2005;
Farmer et al., 2005; Tentori et al., 2010; Tucker and Fields, 2003).
It is promising that the manipulation of PARP was the most effective treatment in all four
of the cell lines tested. Although there are several studies that would augment these
studies, based on results and conclusions presented at this time, manipulating the
expression or activity of PARP-1 appears to be a worthwhile pursuit for use as an
adjuvant to TMZ in GBM treatment. Further research using more potent and specific
PARP inhibitors is underway and should reinforce the data presented herein.
Additionally, as progress is made in siRNA-based therapies, this will offer a specific
platform for targeting PARP-1, or other proteins of interest. This may be especially
important in GBM therapy as wafers releasing PEI-siRNA complexes could be implanted

in the cavity during surgery, releasing treatment molecules in to a defined area.
Moreover, as clinical trials with PARP inhibitors in other cancers continue to give
promising results, additional studies of PARP inhibitors in glioblastoma will lead the way
in determining whether this may be a viable treatment option.
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APPENDIX A

FIGURES

Figure 1. mRNA presence verification for GAPDH, PARP-1, and MGMT. Cell lines
were, from left to right, U-87, U-138, T-98, and LN-229. Genes of interest were GAPDH,
PARP-1, and MGMT. All cell lines showed bands for each of the genes of interest after
reverse transcriptase amplification from fresh mRNA samples.
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Figure 2. MGMT silencing in U-138 cells at a single time point. Quantitative real-time
PCR gene expression results for MGMT expression in U-138 cells. Relative quantity
(RQ) is shown on the Y-axis. Expression was analyzed at 24 hours in untreated U-138
cells and MGMT siRNA treated cells. MGMT siRNA treated U-138 cells had a
significantly lower MGMT gene expression level relative to the untreated U-138 cells.
P=0.0031.
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Figure 3. MGMT silencing in T-98 cells at three time points. Quantitative real-time
PCR gene expression results for MGMT expression for silencing in T-98 cells over three
consecutive time points. Relative quantity (RQ) is shown on the Y-axis. Expression was
analyzed from mRNA samples extracted from untreated control cells and MGMT siRNA
treated cells at 24 hours, 48 hours, and 72 hours after silencing. Relative to the MGMT
gene expression levels in the untreated T-98 cells, all three time points showed
significantly lower levels of MGMT expression (P=0.0008). In addition, the lower levels
of expression were carried through the three consecutive time points. A repeated
measures ANOVA indicated each time point significantly differed from the untreated
control. The time points did not differ from each other.
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Figure 4. Baseline expression of PARP-1 in four cell lines. Quantitative real-time PCR
was used to analyze gene expression of PARP-1 in four cell lines. Relative quantity (RQ)
is shown on the Y-axis. The cell line with the highest gene expression of PARP-1 was U87. The relative to the U-87 cell line, U-138, LN-229, and T-98 cell lines had comparable
PARP-1 gene expression levels. The level of expression of PARP-1 was significantly
greater in the U-87 cell line than the other three cell lines (P=0.0001) when analyzed.
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Figure 5. PARP-1 silencing at a single time point in LN-229 cells. Quantitative realtime PCR gene expression results for PARP-1 expression comparison in LN-229 cells.
Relative quantity (RQ) is shown on the Y-axis. Expression of PARP-1 was analyzed at
24 hours in untreated LN-229 cells (left) and PARP-1 siRNA treated LN-229 cells
(right). Relative to the untreated LN-229 control, the PARP-1 siRNA treated cells
showed 65% lower levels of gene expression.
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Figure 6. PARP-1 silencing at three consecutive time points in T-98 cells.
Quantitative real-time PCR gene expression results show PARP-1 expression in T-98
cells. Relative quantity (RQ) is shown on the Y-axis. Analysis was done on mRNA
extracted from PARP-1 siRNA treated cells at 24 hours, 48 hours, and 72 hours after
silencing, and an untreated control is shown at the far left. Relative to the untreated T-98
control sample, the PARP-1 siRNA treated cells showed striking significantly lower
levels of PARP-1 gene expression (24h, 48h, and 72h samples), (P=0.0003). In addition,
the level of gene expression appears to decrease over the three consecutive time points,
however, time points were not significantly different from each other.
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Figure 7. MGMT expression in U-138 cells after combination silencing. Quantitative
real-time PCR gene expression analysis showing MGMT expression in U-138 cells at a
single time point, 24 hours. Untreated control cells (left) show baseline MGMT
expression. The middle bar represents MGMT expression in U-138 cells after silencing
with MGMT siRNA. Expression of MGMT after treatment with combined MGMT and
PARP-1 siRNA is shown on the right. The untreated control U-138 cells showed
significantly higher levels of gene expression than either of the treated U-138 samples
(P=0.0002). The levels of gene expression between U-138 cells treated with only MGMT
siRNA (middle) or both MGMT and PARP-1 siRNAs showed decreased levels of
MGMT expression compared to untreated, and were not significantly different from each
other.
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Figure 8. PARP-1 expression in U-138 cells after combination silencing. Quantitative
real-time PCR gene expression analysis showing PARP-1 expression in U-138 cells at a
single time point, 24 hours. Untreated control cells (left) show baseline PARP-1
expression. The middle bar shows the level of PARP-1 expression in U-138 cells treated
with PARP-1 siRNA only. On the right, PARP-1 expression in U-138 cells treated with
combined MGMT and PARP-1 siRNA is shown. Relative to the untreated control, cells
treated with PARP-1 siRNA or combined PARP-1 and MGMT siRNA showed
significantly lower levels of PARP-1 gene expression (P=0.0001), but did not differ from
each other.
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Figure 9. Dose dependent response to TMZ in four cell lines. Shown above are the
results from a 24 hour treatment of four cell lines with increasing concentrations of TMZ
(from untreated to the highest treatment group, 2000 µM). Analysis of the best fit curves
confirmed there was significant differences between some lines (P<0.0001).
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Figure 10. TMZ dose response curve at 48 hours. All four cell lines were analyzed at
48 hours after treatment, shown above.
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Figure 11. TMZ dose response curve at 72 hours. All four cell lines were analyzed at
48 hours after treatment, shown above.
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Figure 12. Time course dose response to TMZ in the U-87 cell line. Dose response
curves to TMZ were generated at 24, 48, and 72 hours in the U-87 cell line, with
statistical analysis as previously discussed. The curves show significant differences
(P<0.0001) and no outliers were found leaving 27 data points.
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Figure 13. Time course dose response to TMZ in the U-138 cell line. At each time
point (24, 48, or 72 hours) a dose response curve to TMZ was generated for the U-138
cell line. The curves were significantly different (P=0.0264) and there were no outliers.
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Figure 14. Time course dose response to TMZ in the T-98 cell line. Response to TMZ
was analyzed in the T-98 cell line at three time points: 24, 48, and 72 hours. These curves
were not significantly different from each other (P=0.2748), and no outliers were
reported.
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Figure 15. Time course dose response to TMZ in the LN-229 cell line. Dose response
curves to TMZ were generated at 24, 48, and 72 hours n the LN-229 cell line as
previously described. The curves showed differences between them, (P=0.0102), with no
outliers.
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Figure 16. Effective concentration of TMZ at 24 hours in four cell lines. The effective
concentration (EC50) of TMZ at 24 hours in four cell lines. The EC50 values differed
significantly (P<0.0001). The U-87 median EC50 was 410.6 µM TMZ. The U-138 cell
line median EC50 was 1135 µM TMZ. The T-98 cell line median EC50 was 1364 µM
TMZ, and the LN-229 cell line had a median EC50 of 736.9 µM TMZ.
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Figure 17. Effective concentration of TMZ at 48 hours in four cell lines. EC50 values
were significantly different from each other (P>0.0001). At 48 hours, the U-87 median
EC50 increased to 970.0 µM TMZ. The U-138 cell line median EC50 decreased at 48
hours to 860.0 µM TMZ. The T-98 cell line median EC50 was 1305 µM TMZ, the LN229 cell line had a median EC50 of 543.7 µM TMZ.
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Figure 18. Effective concentration of TMZ at 72 hours in four cell lines. TMZ EC50
values of the four cell lines at 72 hours showed that they were not significantly different
when compared (P=0.0659). The median EC50 values for all four cell lines were: 859.5
µM TMZ (U-87), 696.0 µM TMZ (U-138), 1048.0 µM TMZ (T-98), and 811.9 µM TMZ
(LN-229).
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Figure 19. U-87 temozolomide EC50 over three time points. The U-87 cell line had
EC50 values that were significantly different from each other when analyzed (P=0.0012).
The EC50 at 24 hours was highly significantly different than the 48 and 72 hour values.
The 48 and 72 hour values were not significantly different from one another.
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Figure 20. U-138 temozolomide EC50 over three time points. An ANOVA showed the
U-138 EC50 values were significantly different (P<0.0001). All time points differed.
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Figure 21. T-98 temozolomide EC50 over three time points. The T-98 cell line EC50
values were analyzed and were not significantly different (P=0.3262).
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Figure 22. LN-229 temozolomide EC50 over three time points. EC50 values for the LN229 cell line were significantly different (P=0.0053). The 24 hour values were highly
significantly different from the 48 hour EC50, and the 48 hour value also highly
significantly different than the 72 hour EC50. The 24 hour value was not significantly
different than the 72 hour value.
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Figure 23. Dose response curves for four cell lines treated with TMZ and the PARP
inhibitor 3-aminobenzamide. Shown are the results of a TMZ dose response curve at 72
hours with the addition of a constant concentration of PARPi (33 µM 3-AB). Analysis
confirms differences in the best fit curves (P<0.0001) with the exclusion of a single
outlier from the T-98 cell line (extra T-98 data point in dark green).
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Figure 24. Dose response curves for four cell lines silenced for PARP-1 and treated
with TMZ. Shown are the results of a 72 hour TMZ dose response curve with constant
PARP-1 silencing. Curve analysis confirms the curves are significantly different from
one another (P<0.0001) with the exclusion of six outliers (four in LN-229, shown in dark
red, and two in T-98, shown in dark green).
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Figure 25. U-87 dose response curve comparison for three treatments: TMZ only,
TMZ + PARPi, and TMZ + PARPsil. Data was recorded at 72 hours of treatment for
each group. The best fit curves showed significant differences (P=0.0189) when
analyzed. Inhibition of PARP (PARPi) and silencing of PARP (PARPsil) were constant
and dose dependent response was only assessed for TMZ. No outliers were found in this
analysis.
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Figure 26. EC50 comparison for U-87 cells treated with TMZ only, TMZ + PARPi,
or TMZ + PARPsil. There were significant differences between groups (P=0.0012). The
TMZ only treatment (median EC50 of 859.5 µM TMZ) showed a highly significant
difference from the TMZ + PARPi treatment (median EC50 of 604.2 µM TMZ). The
TMZ only treatment was not significantly different than the TMZ + PARPsil (median
EC50 of 849.1 µM TMZ). The two PARP treatments, TMZ + PARPi and PARPsil were
highly significantly different from each other.
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Figure 27. U-138 dose response curve comparison for three treatments: TMZ only,
TMZ + PARPi, and TMZ + PARPsil. Data was recorded at 72 hours of treatment for
each group. The curves were significantly different from one another (P=0.0487).
Inhibition of PARP (PARPi) and silencing PARP (PARPsil) were done at the same level
constant and dose dependent response was only assessed for TMZ. No outliers were
found.
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Figure 28. EC50 comparison for U-138 cells treated with TMZ only, TMZ + PARPi,
or TMZ + PARPsil. ANOVA analysis showed significance (P=0.0006). The TMZ only
treatment (median EC50 of 696.0 µM TMZ) showed a very highly significant difference
from the TMZ + PARPi treatment (median EC50 of 502.1 µM TMZ). The TMZ only
treatment was not significantly different than the TMZ + PARPsil (median EC 50 of 655.5
µM TMZ). The two PARP treatments, TMZ + PARPi and PARPsil were highly
significantly different from each other.
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Figure 29. T-98 dose response curve comparison for three treatments: TMZ only,
TMZ + PARPi, and TMZ + PARPsil. Data was recorded at 72 hours of treatment for
each group. The curves were significantly different (P<0.0001) from one another.
Inhibition of PARP (PARPi) and silencing PARP (PARPsil) were constant and dose
dependent response was only assessed for TMZ. Two outliers were reported in the
PARPsil treatment group (dark green), and excluded from analysis.
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Figure 30. EC50 comparison for T-98 cells treated with TMZ only, TMZ + PARPi,
or TMZ + PARPsil. ANOVA analysis showed significance (P=0.0381). The TMZ only
treatment (median EC50 of 1048.0 µM TMZ) did not show a significant difference from
the TMZ + PARPi treatment (median EC50 of 771.3 µM TMZ). The TMZ only treatment
was significantly different than the TMZ + PARPsil (median EC50 of 423.2 µM TMZ).
The two PARP treatments, TMZ + PARPi and PARPsil were not significantly different
from each other.
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Figure 31. LN-229 dose response curve comparison for three treatments: TMZ only,
TMZ + PARPi, and TMZ + PARPsil. Data was recorded at 72 hours of treatment for
each group. The curves were not significantly different from one another. Inhibition of
PARP (PARPi) and silencing PARP (PARPsil) were constant and dose dependent
response was only assessed for TMZ. There were three outliers found in this analysis in
the PARPsil treatment group, indicated in dark red.
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Figure 32. EC50 comparison for LN-229 cells treated with TMZ only, TMZ +
PARPi, or TMZ + PARPsil. ANOVA performed on the extrapolated EC50 values
showed significance (P=0.0003). The TMZ only treatment (median EC 50 of 811.9 µM
TMZ) showed a highly significant difference from the TMZ + PARPi treatment (median
EC50 of 1179.0 µM TMZ). Additionally, the TMZ only treatment was highly significantly
different than the TMZ + PARPsil (median EC50 of 453.2 µM TMZ). Finally, the two
different PARP treatments, TMZ + PARPi and PARPsil were also very highly
significantly different from each other.
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Figure 33. Dose response curves for four cell lines silenced for MGMT and treated
with TMZ. Shown are the results at 72 hours of constant silencing of MGMT
(MGMTsil) with dose response curve of TMZ. The curves were significantly different
from one another (P=0.0005). No outliers were found during the analysis.
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Figure 34. Dose response curves for four cell lines silenced for MGMT and PARP-1
and treated with TMZ. Shown are the results from a 72 hour dose response curve of
TMZ in cell double silenced for MGMT and PARP-1 (BOTHsil). The curves were
significantly different from one another (P<0.0001). One outlier (U-138 cell line) was
excluded.
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Figure 35. TMZ dose response curve for four cell lines with constant MGMT
silencing and PARPi treatment. Shown are the results from a 72 hour TMZ dose
response curve where MGMT was silenced in cells and PARP was inhibited with a
constant 33 µM dose of 3-aminobenzamide. Surprisingly, the curves are significantly
different from one another and no outliers were found (P=0.0051).
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Figure 36. Treatment comparisons of EC50 values in the U-87 cell line. Shown are the
EC50 values from 72 hours treatments of the following (from left to right): TMZ only, the
addition of a constant dose of 33 µM 3-aminobenzamide to TMZ (PARPi+TMZ),
addition of constant silencing of PARP-1 to TMZ treatment (PARPsil+TMZ), addition of
constant MGMT silencing to TMZ treatment (MGMTsil+TMZ), addition of silencing
both PARP-1 and MGMT to TMZ treatment (BOTHsil+TMZ), and finally, addition of
PARP inhibition and MGMT silencing to TMZ treatment (PARPi+MGMTsil+TMZ).
The treatment groups were significantly different from each other according to ANOVA
analysis, (P<0.0001). Median EC50 values for each treatment from left to right are as
follows: 859.5, 604.2, 849.1, 1027.0, 739.4, and 599.2 (in µM TMZ concentrations).
Compared to the TMZ only control, the PARPi+TMZ treatment showed a very highly
significant EC50 decrease, however the PARPsil+TMZ treatment was not significantly
different. The MGMTsil+TMZ treatment showed a very highly significant EC50 increase
compared to the TMZ only control. When both PARP-1 and MGMT were (BOTHsil)
with TMZ treatment, the EC50 was highly significantly decreased compared to the TMZ
only treatment. When treated with PARPi+MGMTsil+TMZ, there was a very highly
significant EC50 decrease compared to the TMZ control.
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Figure 37. Treatment comparisons of EC50 values in the U-138 cell line. Shown are
the EC50 values from 72 hours treatments. The treatments are the same as previously
described, and were significantly different (P<0.0001). Median EC50 values for the
treatments from left to right were: 696.0, 502.1, 655.5, 638.2, 546.5, and 901.5 (in µM
TMZ). Compared to the TMZ only control, the addition of a PARP inhibitor highly
significantly decreased the EC50. The single silencing, PARPsil and MGMTsil, were not
significantly different than the TMZ only control. When both PARP-1 and MGMT were
silenced together (BOTHsil), the EC50 was significantly different than the TMZ only
treatment. When MGMT was silenced with PARPi in addition to TMZ treatment, the
EC50 highly significantly increased compared to the TMZ only control.
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Figure 38. Treatment comparisons of EC50 values in the T-98 cell line. Shown are the
EC50 values from 72 hours treatments. The treatments, as previously described, were
significantly different (P=0.0040). From left to right, the median EC 50 values were:
1048.0, 771.3, 423.2, 958.3, 771.8, and 556.6 (in µM TMZ concentrations). Compared to
the TMZ only control, the PARPsil and the PARPi+MGMTsil treatments showed
significantly decreases in the EC50 values. The other three treatments were not
significantly different than the TMZ only control. In addition, the PARPsil treatment was
significantly different than the MGMTsil treatment when compared.
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Figure 39. Treatment comparisons of EC50 values in the LN-229 cell line. Shown are
the EC50 values from 72 hours treatments. Treatments are as previously described, and
were significantly different from each other (P<0.0001). From the TMZ only control to
the PARPi+MGMTsil+TMZ treatment, median EC50 values were: 811.9, 1179.0, 453.2,
1022.0, 1139.0, and 574.1 (in µM TMZ). Compared to the TMZ only control, the
PARPi+TMZ treatment showed a very highly significant increase in EC50, similar to the
highly significant increases in the EC50 values for the MGMTsil treatment and very
highly significant BOTHsil treatment, when compared to the TMZ only treatment. A very
highly significant decrease in EC50 compared to the TMZ only treatment was observed
in the PARPsil treatment and the PARPi+MGMTsil treatment.

